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Introduction 
Snake bite is one of the neglected tropical diseases. There has been a recent increase the 
interest in understanding the mechanism of envenomation caused by snake bites. There 
has been significant geographical variation in the distribution of various snake species in 
India. Within the individual snake species, the patterns of envenomation differ in various 
regions of India. This makes it essential to have region based studies on envenomation 
patterns seen in snake bite patients. 
Most of the current guidelines of diagnosis and prognostication of snake bites uses 
indirect markers which are specific for organ injury caused by various venom proteins in 
the serum. In order to facilitate earlier diagnosis of systemic envenomation before the 
development of complications, it is essential to change the focus of diagnosis of systemic 
envenomation and prognostication to the detection of venom proteins in the serum 
wherever possible. There needs to be a better understanding of various venom proteins 
and their possible mechanism of toxicity in vivo. Unfortunately, there have been 
difficulties in the isolation of different venom proteins. Phospholipase A2 (PLA2) is one 
the enzymes which has been studied as a marker of envenomation. In this study the role 
of PLA2 as a diagnostic marker of snake envenomation is evaluated. 
Hypothesis/Problem statements 
Can serum PLA2 be used as a diagnostic marker for systemic envenomation in snake bite 
and to assess prognosis of snake bite? 
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Aim 
1. To describe the clinical profile of snake envenomation presenting to a tertiary care 
hospital in South India.  
2. To assess the utility of serum PLA2 in diagnosis of snake envenomation and for 
assessment of prognosis in snake envenomation. 
 
Objectives 
1. To study the clinical profile, temporal course and clinical outcome of snake 
envenomation presenting to a tertiary care centre in South India. 
2. To evaluate serum PLA2 level in diagnosis of snake envenomation. 
3. To study the relationship between admission PLA2 levels and the development of 
complications in patients with snake bite. 
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Introduction 
Snake bite is an important occupational and rural hazard in developing countries in the 
tropical region.(1)It is one of the most neglected public health issues in Asia.  There has 
been significant underreporting of the snake bite cases and the mortality associated with 
it. Hence the world wide burden of snake bite is not known.(2) There is significant 
morbidity, mortality and economic burden associated with snake bite. 
 
Epidemiology of snake bite  
The global snake bite initiative has reported that approximately 4,21,000 envenomations 
and 20,000 deaths occur every year due to snake bites. The actual figures may be as high 
as 18,41,000 envenomations and 94,000 deaths. (3) 
In the rural India, only 7.23% of the snake bite deaths were officially reported. There is 
wide geographical variation in proportion seeking medical care ranging between 22-75%. 
In a survey conducted in 30 rural villages in Tamil Nadu, the incidence of snake bite was 
3.9% and the mortality was 0.45%. The economic burden on the family as a result of 
complications of snake bite or delay in treatment was significant and 40% of the victims 
required to take loan to meet the financial need during the emergency.(4) In the ―Million 
Death Study‖ all deaths in about 7,000 randomly chosen sample area were subjected to 
verbal autopsy. Based on the million death study, direct estimate of deaths attributable to 
snake bite in 2005 was 46,000 (99%CI 41,000-51,000), (1 snake-bite death for every 2 
HIV/AIDS deaths). Snake-bites caused 0.5% of all deaths, 3% in 5-14 year-olds. 97% 
died in rural areas, only 23% in health facilities. The highest numbers of deaths were in 
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Uttar Pradesh (8,700), Andhra Pradesh (5,200), and Bihar (4,500). In contrast the 
Government of India’s web-site reported an average of only 1,350 deaths/year between 
2003 and 2008, and Kastururatne et al., 2008 estimated about 11,000 deaths/year.(5) 
Hence there was a marked difference in the prevalence of snake bite which estimated by 
the official registry and direct survey.(5) The highest burden of snake bites occurs in the 
tropical countries of the South Asia, South East Asia and Sub Saharan Africa. 
The large population in rural areas who work outdoors are more prone to snake bites. 
Men are twice as prone to snake bite as women and the age group commonly affected is 
between 15-45 years. Agricultural labourers and construction workers are prone to snake 
bite.  Snake bite is a seasonal disease increasing in prevalence during the rainy season 
between June to September in India.(1)  
 
Geographical distribution of snake species in India 
There are about 3000 species of snakes worldwide of which about 450 are found to be 
dangerous to humans.  In India, there are about 216 species of snakes identified of which 
52 are found to be venomous. (6)The concept of ―Big 4‖ is used to refer  species that 
cause significant mortality in India: Indian Cobra (Naja naja), Common Krait (Bungarus 
caeruleus), Russell's viper (Daboia russelii) and the Saw-scaled viper (Echis 
carinatus).(7) Several species outside the big four cause systemic envenomation in 
specific geographical regions.  The most important among these are the hump nosed pit 
viper envenomation which was first identified and reported from Kerala. It is known to 
cause severe coagulopathy, acute kidney injury and local reaction.  There is no antivenom 
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available for this snake bite and there was clear inefficacy of Indian Antisnake venom in 
reversing the coagulopathy caused by Hypnale hypnale. (8) In the Thar desert region of 
Rajasthan, Echis sochureki or severe saw scaled viper was identified recently. It causes 
severe bleeding manifestations associated with coagulopathy and there is a relative 
inefficacy of polyvalent ASV to neutralise the same. (9) 
The species of venomous snakes that were identified other than the Big 4 in India are 
described below.  
 
1-Monocellate cobra (N. kaouthia) – mostly found in North Eastern India, pattern and 
severity of envenomation similar to that of Naja naja. 
2. Central Asian or Oxus cobra (N. oxiana)- rarely found in the northern parts of India 
like Kashmir and Himachal Pradesh but no bites reported from India. 
3. Kraits (Bungarus)- Three species identified are Wall's krait (Bungarus walli) found in 
the north east India and the Sind krait (B. sindanus) found in Western India. The greater 
Black krait (B. niger) found in Bangladesh is associated with rhabdomyolysis, acute 
kidney injury and neurotoxicity. 
4. King cobra (Ophiophagus hannah)- This is found in the Western Ghats and north 
east India. It is the largest and most dangerous snake but there are fewer bite cases and 
mortality in India. 
5.Pit vipers(Crotalinae)- The most common species found in India is the the Hump-
nosed pit-viper (Hypnale hypnale ) which is found in the Western Ghats and is associated 
with local necrosis, bleeding, coagulopathy and acute kidney injury and frequently 
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misidentified with Echinus carinatus. Malabar pit-viper (Trimeresurus malabaricus) of 
the Western Ghats is associated with local necrosis.  The other species of pit vipers found 
in India include the Bamboo pit-viper (Trimeresurus gramineus) of the Western and 
Eastern Ghats, the Himalayan pit-viper (Gloydius himalayanus) found in Western 
Himalayas, large-scaled pit-viper (Peltopelor macrolepis) of the south-west, northern 
white-lipped green pit-viper (Cryptelytrops septentrionalis), red-tailed pit-viper (C. 
erythrurus), mountain pit-viper (Ovophis monticola) found in north and north east and 
arboreal green pit vipers idenitified in North east.(10) Most of these vipers are associated 
with local swelling with bleeding manifestations and coagulopathy.  
6. Sea-snakes (Hydrophiinae, Laticaudinae)- There have been a few cases reported in 
the coastal regions of India which is associated with myotoxicity. 
 The Indian polyvalent anti-snake venom does not neutralise the venom of these 
snakes(9). 
Snake venom is a secreted by salivary glands of the venomous snakes and contains a 
complex mixture of peptides, glycoproteins and enzymes.(11) These are shown to be 
associated with the  local and systemic envenomation including neurotoxicity, 
haemotoxicity, myotoxicity, nephrotoxicity and rhabdomyolysis associated with snake 
bites.(12)  
 
Clinical profile of snake envenomation in India 
There has been considerable geographical heterogeneity in the clinical manifestations of 
snake bite across India.  
7 
 
Syndromes associated with snake bite  
1. No envenomation 
2. Local swelling  only 
3. Haemotoxicity with / without local swelling  
4. Neurotoxicity only  
5. Neurotoxicity with Local swelling 
6. Haemotoxicity + Neurotoxicity  with / without local swelling 
7. Haemotoxicity + Neurotoxicity +renal failure  with / without local swelling 
 
Syndrome species correlation in snake bite- Studies so far 
The incidence of systemic envenomation occurring in snake bites varies from region to 
region between 10%-34%.(13) Bites from venomous species can manifest with no 
systemic envenomation and are referred as dry bites.  
Clinical patterns in Viperidae bites 
Russell’s viper (Daboia russelii russelii) presents with local swelling, blistering and 
occasionally necrosis at the bite site with associated haemostatic manifestations like 
coagulopathy in 77% of the cases. There were additional features like acute kidney injury 
and neurotoxicity noted with this species.(14)  In contrast, saw scaled viper (Echis 
carinatus) bites are associated with haemotoxicity with local swelling, tissue necrosis and 
blister formation.(15)  The pit vipers bites described in certain parts like Kerala especially 
the hump nosed pit viper (Hypnale hypnale) presents with haemotoxic manifestations like 
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bleeding, coagulopathy, local swelling and cellulitis with or without acute kidney injury 
and brown coloured urine.(8) 
 
Clinical patterns in Elapidae bites 
In Elapidae, the bites by cobra species especially the Naja naja and N. Kaouthia are 
associated with neuroparalytic manifestations with extensive local swelling, cellulitis 
with a high incidence of tissue necrosis and gangrene of the bitten limbs. Elapid bites are 
characteristically associated with descending paralysis which is progressive in nature.(16) 
In contrast, the bites of Common krait (Bungarus caeruleus) is classically painless with 
no features of local envenomation to the extent that the bite site may not be recognised in 
most cases. Usually victims are bitten while sleeping on the floor. There may be severe 
abdominal pain mimicking a surgical emergency. The extra-ocular muscles are most 
commonly involved and ptosis is usually considered as the first sign of early 
neuromuscular blockade. Subsequently the patients may develop bulbar weakness with 
difficulty in swallowing, speaking and protrusion of tongue beyond the incisors. As the 
weakness descends to involve the diaphragmatic muscles, respiratory symptoms develop 
which can be life-threatening without prompt intubation and ventilation. There is also 
loss of tendon reflexes and weakness of the limbs noted in a few cases.(17)  
According to the WHO algorithm for the South East Asian Countries the following 
syndromes were defined to correlate with the snake species. 
Syndrome 1- Local envenomation with bleeding and clotting disturbances associated 
with Viperidae 
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Syndrome 2-Local envenomation with bleeding and clotting disturbabnces with shock or 
acute kidney injury –Russell’s viper 
The above symptoms with conjunctival edema and acute pituitary insufficiency has been 
described with Russell’s viper envenomation in Myanmar and South India. 
The above symptoms with neurotoxicity like ptosis, external ophthalmoplegia, facial 
paralysis and dark coloured urine has been described for Russell’s viper envenomation in 
South India, Sri Lanka and Myanmar. 
Syndrome 3- local envenomation with paralysis- Cobra /King cobra 
Syndrome 4: Paralysis with minimal or no local envenoming: 
Bitten on land while sleeping on the ground with/without abdominal pain is associated 
with krait 
Bitten in the sea, estuary or freshwater lakes -sea-snake 
Syndrome-5 Paralysis with dark brown urine and acute kidney injury 
Above symptoms + bitten on land/bleeding and clotting disturbances- Russell’s viper 
Above symptoms+ bitten in sea, estuaries without bleeding and clotting disturbances- sea 
snakes 
Clinical features and complications of snake envenomation 
The immediate symptoms that arise from snake bite are mostly related to anxiety and fear 
like chest pain, flushing, palpitations, dyspnoea, syncope and loss of consciousness. 
Sudden cardiac arrest is also reported very rarely.(18) The occurrence of these symptoms 
do not relate to envenomation and has a similar incidence irrespective of the species of 
the snake.  
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Neurotoxicity associated with snake bite is manifested by ptosis, ophthalmoplegia, bulbar  
and limb weakness and respiratory muscle including diaphragmatic paralysis. The 
prevalence of neurotoxicity is much higher in the Northern(19) and Western parts(20) of 
India when compared to the incidence of haemotoxicity. The most common snakes 
associated with neurotoxicity are Common krait, Cobra and Russell’s viper in certain 
areas.  
Haemotoxicity is associated with bleeding manifestations like bite site bleeding, oral 
cavity and gum bleeding, internal bleeding manifestations like hematemesis and melaena 
and hematuria. It is mostly associated with viperine bites which constitute the major 
envenomation pattern in South India.(21)  
The cardiac manifestations occur rarely with viperine bites. The manifestations include 
tachycardia, bradycardia, atriventricular block, hypotension, pulmonary edema, left 
ventricular systolic dysfunction associated with myocarditis and cardiogenic shock. 
Acute coronary syndrome with myocardial infarction associated with snake bite has been 
reported.(22) 
The mechanisms involved in snake bite related nephrotoxicity are multiple including 
hemorrhage, hypotension, venom induced consumptive coagulopathy, hemolysis, 
haemoglobinuria and direct venom related nephrotoxicity. The pathological changes 
observed in the kidney are acute tubular necrosis (found in almost 100% of the biopsy 
specimens) varying from focal and patchy to diffuse.  Acute cortical necrosis is seen in 
around 25% of the biopsy specimens of snake bite patients with renal failure. Very rarely 
proliferative glomerulonephritis and interstitial nephritis also has been observed patients 
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with renal failure. (23)The data on clinic-pathological correlation  published previously 
from our center was based on 19 patients with snake bite induced AKI who underwent 
renal biopsy. Of the 19 patients, the majority (n=12) had acute tubular necrosis which 
resolved with a few patients requiring dialysis. 4 patients had normal renal biopsy and the 
AKI resolved without dialysis in all of them. The patients (n=3) who progressed to 
develop chronic kidney disease had acute cortical necrosis in the renal biopsy and they 
subsequently went on to become dialysis-dependent.(24) 
Myotoxicity has also been described with Elapidae and viperidae species. It involves the 
skeletal and cardiac muscles and presents initially as myalgia which progresses to 
rhabdomyolysis. The myoglobin released into the blood from the damaged muscles gets 
accumulated in the renal tubules causing acute kidney injury and myoglobinuria. It is 
characterised by elevation of CPK and LDH. (11) Cardiac muscle involvement typically 
manifest as myocarditis.(22) 
 
An overview on Daboia russelii / Russell’s Viper syndrome 
Russell’s viper is a common cause of systemic envenmation in India, Sri Lanka and 
Myanmar.(25)Russell’s viper accounts for 30-40% of the patients with systemic 
envenomation from the Sri Lankan study. More importantly it accounts for the most fatal 
envenomation by any snake in this geographical region. The clinical syndrome of 
Russell’s viper has been described by WHO for the South Asian countries. The classical 
presentation includes severe pain and swelling at the bite site with local bleeding. Most 
patients develop swelling that extends more proximally to involve the joints and can lead 
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to compartment syndrome and necrotising fasciitis. There is also associated regional 
lymphadenopathy which could be regarded as a sign of systemic envenomation. Local 
envenomation is the most common manifestation of Russell’s viper envenomation 
accounting to 91.9% of all the bites. (26)There is associated coagulopathy which 
manifests as clinical bleeding manifestations like hematuria, haematemesis and melaena 
which can be often life-threatening. Minor bleeding manifestations include oral and gum 
bleeding and bleeding from the bite site. Coagulopathy is the second most common 
manifestation in patients with Russell’s viper envenomation accounting for 76.1%.(26) 
The Indian polyvalent venom was found to be inefficacious in neutralising the 
coagulopathy in Russell’s viper bite in Sri Lanka.(26) There are also case reports of 
thrombotic microangiopathy developing post Russell’s viper envenomation requiring 
plasma exchange. (27) Renal dysfunction is a characteristic feature of Russell’s viper 
envenomation which can be used to distinguish it from other viper bites like Saw scaled 
viper. The mechanism of Russell’s viper envenomation related nephrotoxocity include 
shock, venom induced consumptive coagulopathy, intravascular haemolysis, 
rhabdomyolysis, direct nephrotoxic effect of the venom, ASV related interstitial nephritis 
and sepsis related secondary AKI. (28)  Use of native medications and thereby late 
presentation to hospital and ASV administration has been one of the predictive factors for 
Russell’s viper related AKI especially in the paediatric population. (28) Nearly one fifth 
(18.7%) of the patients developed acute kidney injury following Russell’s viper bite in 
Sri Lanka.(26) Abdominal pain is a symptom that is evaluated to have good correlation 
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with in incidence of coagulopathy and neurotoxicity and its severity correlated with the 
severity of these syndromes. (26)  
Neurotoxicity is a syndrome of Russell’s viper that has received considerable attention in 
view of its intra-species geographical heterogeneity of presentation. It was reported more 
frequently in patients with Russell’s viper bite from Sri Lanka.(29) The most common 
manifestation of neurotoxicity was ptosis (almost 100%) followed by blurring of vision 
(93%) and ophthalmoplegia (90%). The incidence of bulbar weakness, respiratory muscle 
weakness and limb weakness are not reported in the Sri Lankan study. (29) There was no 
residual neurological deficit noted in any patient at 6 weeks or 6 months. The 
ophthalmoplegia had the longest duration. Most patients developed neurotoxicity within 
8 hours of bite and ptosis resolved within 3 days although ophthalmoplegia lasted for 4-5 
days. It was shown that neurotoxicity was associated with larger snakes of Russell’s viper 
species and was associated with higher venom concentrations.(29) The neurotoxicity in 
Russell’s viper is attributed to a pre-synaptic neurotoxin, U1-viperitoxin-Dr1a, which is a 
phospholipase A2 subtype of venom toxin found in Russell’s viper. (30)  
Acute pituitary insufficiency following Russell’s viper envenomation is a rare entity that 
has been described in various parts of India, Burma and lately from Sri Lanka. The 
presentation is hypotension following snake bite without any evidence of sepsis or 
cardiac failure explaining the shock and responds promptly to intravenous steroids like 
dexamethasone. (31) The mechanisms proposed for Russell’s viper bite related 
hypopituitarism were pituitary infarct caused by fibrin microemboli as a result of the 
procoagulant action of the venom toxins and pituitary hemorrhage as a result of 
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hamorrhagins present in the venom. The hypothalamo-pituitary adrenal axis is involved 
most commonly in acute pituitary insufficiency following Russell’s viper envenomation 
presenting as hypoglycaemia and hypotension. Steroids are lifesaving in these cases. 
Chronic pituitary insufficiency involves all pituitary axes and requires hormone 
replacement.(32) In a prospective study of pituitary failure after Russell’s viper bite in 
Myanmar, of the 9 patients in shock after Russell's viper bites and in 24 individuals who 
had been severely envenomed, 4 who died had pituitary haemorrhage and 7 who were 
alive had evidence of hypopituitarism. 
Cerebrovascular accident is a rare complication of Russell’s viper envenomation. The 
incidence of large and medium vessel infarct in the brain in Russell’s viper envenomation 
was 1.8%  in Srilanka (n=9).(33) The etiology of cerebrovascular accident in Russell’s 
viper envenomation is proposed to be the formation of fibrin microthrombi which may 
get embolised to the brain. The patients having permanent neurological deficits are 
associated with higher morbidity and mortality. (33) 
 
Correlation of clinical syndromes to species 
In most studies a very low percentage of patients bring the snake that has bitten the 
patient to the hospital. Therefore the clinical syndrome of the patient is important in 
trying to identify the potential snake that has bitten the patient. Syndrome species 
correlation studies are required in different regions to develop algorithms for clinical 
diagnosis. An example of such a study was conducted by Ariaratnam et al (2009). Such 
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studies have not been conducted in India and are urgently required in view of the in view 
of the diversity of snakes and variability of syndromes..  
 
Table 1-Clinical spectrum of syndromes of snake bites, Sri Lanka(34) 
 
Species No Local 
effects(%) 
Coagulo 
pathy 
(%) 
Neuro 
toxicity 
(%) 
Renal 
toxicity 
(%) 
Myo 
Toxicity 
(%) 
Russell’s viper 319 96 76 59 19 24 
Hump-nosed 
pit viper 
302 91 39 _ 10 _ 
Common krait 88 9 _ 95 _ _ 
Cobra 45 91 _ 80 _ _ 
 
 
Table-2 Sensitivity and specificity of clinical syndromes as a screening test in 
identifying snake bites, Sri Lanka 
 
Snake                                              Sensitivity (%)                   Specificity (%) 
Russell’s viper                                         14                                     100 
Cobra                                                       78                                       96 
Common krait                                          66                                     100 
Hump-nosed viper                                   10                                       97 
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Figure 1, from ―Guidelines for snake bite management, WHO South East Asia 2016   
Figure 1  
 
Management of snake bite patients 
First aid and transport 
The victim should be reassured and the affected limb has to be immobilised. Searching 
for the snake, handling of the snake and killing it is not recommended.  Accelerated 
transport to medical care in recovery position is ideal. Tight arterial tourniquet is not 
recommended. Traditional practices for snake bite management are shown to be more 
harmful and delay the initiation of ASV. 
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Anti-snake Venom (ASV) 
The polyvalent ASV that is manufactured in India is isolated from the serum of horses 
after injecting the snake venom by fractionation of the plasma. The polyvalent antisnake 
venom has antibodies against the Big 4 species of India associated with systemic 
envenomation namely Russell’s viper, saw scaled viper, Common krait and Indian 
cobra.(35) Although monovalent antivenom is considered more efficacious, the approach 
across the country has been polyvalent ASV use because the identification of biting 
species may not be possible.  
Dose of anti- snake venom 
There is no consensus on the intial dose of ASV that needs to be administered in patients 
with systemic envenomation. The usual practice is to administer 10 vials with careful 
monitoring of signs of hypersensitivity reaction and anaphylaxis.(36)  The patient should 
be closely monitored and reassessed every 4-6 hours for resolution of envenomation 
symptoms. If there is persisting neurotoxicity or haemotoxicity, then the dose is repeated.  
There have been several trials comparing low dose ASV(6 vials initially) to high dose 
ASV(12 vials initially) in patients with systemic envenomation which showed no 
statistical difference in the resolution of envenomation syndromes or outcome of patients 
between the two groups.(37) However these studies were of small sample size, did not 
confirm biting species and had limitations in design. A larger well designed RCT was 
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conducted in Nepal where they compared slow administration of ASV ( 2 vials initial 
push followed by 4 vials every 4 hours for 12 hours and 2 vials for the next 2 hours) 
against 10 vials in the first hour of presentation. This trial showed no significant 
difference in the outcome in both the arms in the resolution of envenomation symptoms 
and the incidence of antivenom reactions (in Publication references in WHO guidelines 
for South East Asia 2016).  
A systematic review published in 2015 on the various trials on high and low dose ASV 
concluded that there was no significant difference in the resolution of haemotoxicity, 
neurotoxicity, incidence of acute kidney injury, duration of hospital stay or mortality 
between low and high dose ASV regimens. However there was a significant cost 
effectiveness associated with the low dose regimen.(38) There is urgent need for well 
conducted dose finding studies in India to establish the exact dose for Antisnake venom. 
Problems and limitations of anti-snake venoms 
The success of antivenom treatment depends of the ability of the antibodies to bind, 
neutralise and eliminate the toxins injected into the body and thereby reversal of the 
clinical and laboratory manifestations of snake envenomation.  The polyvalent ASV is 
able to neutralise the circulating antibodies but there is controversial evidence on the 
reversal of tissue and end organ damage.(19) There has been a clinical inefficacy of 
polyvalent ASV in reversing the neurotoxicity of Krait envenomation requiring higher 
doses in patients with Krait bite.(19) This is probably because of irreversible binding of 
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neurotoxic venom proteins to presynaptic nerve terminal causing nerve terminal 
degeneration.  
In a study of Russell’s viper bite in Sri Lanka 30% of definite and 40% of probable 
Russells’ viper envenomation required more than 20 vials of antivenom. In a randomised 
controlled trial comparing Haffkine equine polyspecific antivenom to a new 
monospecific ovine Fabantivenom (Polonga TAb) in Russell’s viper envenomation,  it 
was found that 70% of Russell’s viper envenomation was neutralised with 10 vial of 
Haffkine’s polyvalent antivenom but it was associated with high rates of hypersensitivity. 
In South India our clinical experience has been that there is clinical inefficacy of 
polyvalent antivenom in Russell’s viper envenomation. However there are no published 
studies which corroborate this. 
The geographical variation in the snake venom toxins and antigenic properties across 
India also leads to variable efficacy of ASV. The source of venom for ASV manufacture 
is primarily obtained from the Irula cooperative in Mammallapuram. (39) 
There are serious adverse events associated with the use of polyvalent ASV like 
pyrogenic reactions, hypersensitivity reactions, anaphylaxis and late onset serum 
sickness. This limits the administration of ASV in patients with severe envenomation. 
Low dose adrenaline administered subcutaneously is found to be effective in the 
treatment of anaphylaxis due to ASV.(40) The other issues of ASV include the irregular, 
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insufficient supply and its high cost Indian setting where most of the victims are from the 
low socioeconomic strata. (41) 
 
Local envenomation 
According to the WHO guidelines, ASV should be administered for swelling and pain 
extending more than half the bitten limb within 48 hours or rapid progression of swelling 
beyond wrist/ankle within few hours, swelling after bite on digits and regional 
lymphadenopathy. Immobilisation with limb elevation is advisable. Antibiotics are 
indicated if there is local cellulitis/necrotising fasciitis. The latter may also require 
surgical debridement. 
Haemotoxicity 
The indication for ASV administration include spontaneous systemic bleeding 
manifestations, coagulopathy defined as positive non clotting whole blood clotting time 
more than 20 minutes or INR >1.2 or prothrombin time 4-5 seconds longer than the 
control time or thrombocytopenia of <1,00,000 /mm3. The parameters are repeated every 
6 hours and if there is persistence of coagulopathy or systemic bleeding, then ASV 
further dose of ASV is given. Persistence of coagulopathy beyond 20 vials of ASV may 
warrant the use of blood products like fresh frozen plasma or cryoprecipitate. 
Neurotoxicity 
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Any neurotoxic manifestation at admission, bilateral ptosis, external ophthalmoplegia and 
paralysis requires ASV at admission and the patient has to be reassessed every 6 hours 
for resolution of signs and symptoms. Evidence of respiratory muscle weakness like 
diaphragmatic and intercostals muscle weakness will require mechanical ventilation. 
Acute kidney injury 
The patient may have oliguria, anuria, hemoglobinuria, myoglobinuria, rising 
creatinine/urea levels, evidence of rhabdomyolysis and intravascular haemolysis. ASV 
has to be administered for these situations and the patient needs to be monitored for the 
need for renal replacement therapy.  
 
Venom proteins responsible for clinical manifestations 
The toxic component of snake venom is classified into enzymes, polypeptides, 
glycoproteins and compounds with low molecular weight. There are at least 26 different 
enzymes that are detected in snake venom of which 12 enzymes are found to be common 
in all species of snakes.(42) The enzymes include fibrinogenolytic enzymes such as 
Alpha-fibrinogenases, Beta-fibrinogenases, and Gamma-fibrinogenases. Other enzymes 
include plasminogen activator releasers  such as Ecarin, prothrombin activator, 
prothrombinase complex formation inhibitors such as Phospholipase A2,B,C and D, 
Factor X-activator, Factor V-activator,  Factor XI-activator,  Protein-C-activator,  
fibrinogenolysin, Platelet aggregation inducers, either without coagulant activity, or with 
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coagulant activity ,Platelet aggregation inhibitors, such as alpha fibrinogenases or 5-
Nucleotidase, or ADPase, or fibrinogen receptor antagonists, Von Willebrand factor-
dependent platelet aggregation inducers. Zinc metalloproteases, which disrupt the 
endothelial lining of blood vessels causing spontaneous bleeding, hyaluronidases 
(spreading factor), arginine esterases and, L-amino acid oxidases which is widely found 
in snake venoms, and is responsible for the yellow coloration of snake venom due to the 
presence of riboflavin as a prosthetic group(43) 
L-amino acid oxidase acts by causing oxidative deamination of the amino acids, 
inhibition of platelet aggregation,  induction of apoptosis, hemorrhagic effects and 
cytotoxicity. The other enzymes in snake venom include phosphodiesterases, 
phosphatases, choline- esterases, transaminases, proteases, 5- nucleotidases, esterases, 
ATPase, RNAase which account for toxicity which are not part of acute 
envenomation.(44)  
This is a summary of the few major primary compounds that are detected in the 
venom of some of the most common families of snakes in South Asia and their probable 
mechanisms of actions. 
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Table 3 showing the various venom proteins and their proposed mechanisms 
of action 
Type  of compound Action on body Snake family 
Acetyl choline esterases AchE Tetanic paralysis Colubridae, Elapidae 
Arginine esterases 
Believed to predigest 
prey 
Viperidae 
Bradykinin potentiating peptides 
Pain, hypotension, 
immobilize prey 
Viperidae 
C- type lectins 
Modulate platelet 
activity, prevent 
clotting 
Viperidae 
Cysteine rich secretory proteins 
Believed to induce 
hypothermia and 
immobilize prey 
Colubridae, 
Elapidae,Viperidae 
Disintegrins 
Inhibit platelet activity 
and promote 
hemorrhaging 
Viperidae 
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Hyaluronidases 
Increase interstitial 
fluidity aiding in the 
dissemination of 
venom proteins 
Elapidae, Viperidae 
L-Amino acid oxidases Cell damage, apoptosis Elapidae, Viperidae 
Metalloproteinases 
Hemorrhage, 
myonecrosis, believed 
to predigest prey 
Atractaspididae, 
Colubridae, Elapidae, 
Viperidae 
Myotoxins 
Myonecrosis, 
analgesia , immobilise 
prey   
Viperidae 
Nerve growth factors 
Believed to cause cell 
apoptosis 
Elapidae, Viperidae 
Phosphodiesterases 
Causes hypotension 
and shock 
Colubridae, Elapidae, 
Viperidae 
Phospholipases A2(PLA2) 
Causes myotoxicity, 
myonecrosis, damage 
to call membranes 
Colubridae, Elapidae, 
Viperidae 
PLA2 based presynaptic 
neurotoxins 
Immobilises prey Elapidae, Viperidae 
Prothrombin activators 
Disseminated 
intravascular 
coagulation (DIC) 
Elapidae 
Purines and pyrimidines 
Hypotension,  
paralysis, apoptosis, 
necrosis, 
immobilisation of prey 
Elapidae, Viperidae 
Sarafotoxins 
Myocardial ischemia, 
increased blood 
pressure, disturb heart 
rhythm 
Atractaspididae 
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Serine proteases 
Disrupts hemostasis, 
hypotension,  
immobilize prey 
Colubridae, Viperidae 
Three finger toxins (3FTx) 
Rapid immobilisation 
of prey, paralysis and 
death 
Colubridae, Elapidae 
Venom proteins responsible for specific envenomation syndromes 
Each envenomation syndrome was attributed to multiple venom proteins.  
Table 4 demonstrates the correlation between specific enveomation syndrome and 
venom proteins. 
Specific envenomation 
syndromes 
Venom proteins responsible 
Swelling and bruising Venom endopeptidases, metalloproteinase haemorrhagins, 
phospholipases, endogenous autacoids like histamine, serotonin 
and kinins. 
Hypotension and shock Oligopeptides and vasodilating autacoids 
Platelet and coagulation 
abnormalities 
Venom phospholipases, Zinc metalloproteinases. 
Neurotoxicity Phospholipase A2, alpha and beta bungarotoxins, acetylcholine 
esterases. 
Myotoxicity Phospholipase A2 myotoxins, and metalloproteinases 
Acute kidney injury Venom phospholipase A2 and metalloproteases 
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Increased capillary 
permeability 
Metalloproteases. 
 
 
Diagnostic tests for snake envenomation 
 
1. 20 minute whole blood clotting time test (20WBCT) 
It is a useful, informative and bedside test with almost no requirement for trained 
personnel. Absence of clotting of a 2ml blood sample in a snake bite patient at 20 
minutes indicates the presence of coagulopathy. In South East Asian countries, this is 
the most simple test that can distinguish Viperidae bites which are associated with 
coagulopathy from dry bites and Elapidae bites. 
False positive results in 20WBCT is seen in cases where the tube is made of materials 
other then glass like plastic, polypropylene, polystyrene and in glass containers which 
are washed with detergent which prevents activation of Hageman factor on contact of 
glass with the blood. Hence the glass used for clotting tests has to be washed with 
0.9% normal saline only.  
There are false negatives associated with 20WBCT. A non clotting 20WBCT is 
predictive of a fibrinogen concentration of <0.5g/l with more than 90% sensitivity and 
specificity.(45) However, mild coagulopathy may be missed and this may result in 
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delay in ASV administration. Hence WHO recommends ASV administration in the 
presence of clinical bleeding manifestations even with normal 20WBCT and periodic 
monitoring of 20WBCT to detect delayed envenomation. Coagulation parameters like 
PT, APTT and fibrinogen needs to be measured if venom induced consumptive 
coagulopathy is suspected. 
2 .Enzymatic assays for diagnosis of snake envenomation- A review of Phosholipase 
A2 
 
Phospholipase enzymes 
Phospholipases are enzymes that break down or hydrolyse the glycerophospholipids. 
Depending of the site of hydrolysis, the are divided into 5 types namely, phospoholipase 
A1 which hydrolyses at the sn-1 site and phospholipase A2 at the sn-2 site. 
Phospholipase B acts at both these sites. Phospholipase C acts on the glycerophosphate 
bond where as phospholipase D removes the polar head group. (46) 
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Figure 2 depicting the site of cleavage of different phospholipase enzymes. 
Phospholipase A2 as predictor of systemic envenomation  
It has been described that the serum phospholipase  levels are elevated in viperidae and 
elapidae bites when compared to patients with no envenomation.(47) The need for a rapid 
and reliable diagnostic test to detect snake envenomation particularly in the context of 
limited availability of antisnake venom and the high rates of allergy and anaphylaxis.(48) 
The clinical relevance is that most of the current decisions and protocols on ASV 
administration are strictly based on clinical features and development of complications 
after which ASV may not have much role. It is hence necessary to detect systemic 
envenomation at an earlier stage to enhance appropriate early administration of ASV in 
snake bite patients. 
 
Mechanism of action of PLA2 
Phospholipases are a enzymes which are capable of calcium 2+  ion dependent hydrolysis 
of the phospholipids of the cell membrane of the cells cleaving phosphoglycerides into 
free fatty acids and lysophospholipids. This enzyme is found in all forms of life and has a 
very significant role in regulation of phospholipid turn over at the cell membrane, the 
maintenance of membrane fluidity and trafficking, cell maturation and maintenance. It is 
also involved the regulation of normal apoptosis and the eicosanoid production involving 
prostaglandins and leukotrienes.  Hence this enzyme is also implicated in the structural 
damage of the cell and the spread of venom resulting in local and systemic 
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envenomation. The hydrophilic region of the cytotoxin gets surrounded by the released 
fatty acids which permit the cytotoxin to be released from the enzyme-cytotoxin complex 
facilitating the spread of cytotoxin.(49) There is destruction of phospholipids on the 
extracellular as well as cytoplasmic side promoting cell death. There is concomitant 
endogeneous lipase stimulation and it is not known whether the cytotoxic effect could be 
fully attributed to exogeneous PLA2 of the snake venom. There is myotoxicity associated 
with PLA2 which is inflammatory in nature mediated by the enzymatic stimulation of 
arachnoid acid metabolites and non-catalytic nociceptive effects.(50) The inflammatory 
action of phospholipases  has been shown to be associated with increase in vascular 
permeability.(51) The active catalytic form MT III(Myotoxin III) with Asp at 49
th
  
position  and the inactive catalytic form of PLA2, MT II(Myotoxin II) with Lysine 
variant at 49
th
 position are shown to have phagocytic  and cytotoxic effects.(52)  
The venom PLA2 has affinity to the synaptic cleft and acts presynaptically to cause 
destruction of the motor nerve terminal due to its enzymatic activity. This is one of the 
proposed mechanism that accounts for the neurotoxicity in patients with snake bite. The 
factors that mediate the binding of PLA2 to the synaptic cleft are not fully understood. 
(53) The hemotoxicity due to PLA2 is due to its antiplatelet aggregating activity, 
anticoagulant and hemolytis action. Increase in vascular permeability is associated with 
hypotension. Other pharmacological actions include bactericidal effect and stimulation of 
inflammatory response.(49) 
PLA2 is a superfamily of enzymes with almost 15 subgroups. The 4 main types include  
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PLA2 (s PLA2), cytosolic PLA2(c  PLA2), calcium independent PLA2  (i PLA2) and 
lipoprotein associated PLA2 (Lp PLA2) of which the secreted PLA2 is found mostly in 
the snake venoms.(54) 
   
Biochemical properties of phospholipase A2 
The venom derived s PLA2 is further divided to 4 subtypes, types 1,2,3 and 4. Types 1 
and 2 are derived from snakes and 3 and 4 are of special biological interest derived from 
other species like Gila monster but not from snakes. (46) These secreted PLA2 was found 
in the venom of sea snakes, crotalids, vipers and elapids. There are individual variations 
in the composition of different secretory PLA2 in the venom of these different snakes. 
The venom of old world snakes are almost similar to the secretory PLA2 of group 1a, but 
has an additional C terminal tail and different organization of disulphide bonds hence 
referred to as 2b sPLA2. A subgroup of this protein called 2b sPLA2 with a lysine instead 
of aspartate at 49 th position has decreased catalytic activity and calcium binding but has 
high levels of cytotoxicity and myotoxicity. This is found exclusively in viperids.(46) 
The beta bungarotoxin which is a major toxin responsible for the neurotoxicity in kraits 
has 2 chains of which chain A is formed by a type 1 s PLA2. Hence phospholipase A2 is 
found in different combinations in the venoms of different snakes.  
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PLA2 in different snake species in India 
There are about 20 different toxic enzymes known which are attributed to systemic 
envenomation in snake bites and PLA2 is one among them. PLA2 is one of the 
constituent of the snake venom found in Elapids and Viperidae.(55) Since it is only one of 
the enzymes present in the venom, it may not attribute to all the clinical manifestations of 
patients with snake bite. However, in the Indian scenario where most of the venomous 
bites are contributed by Viperidae and Elapidae family of snakes, assessment of PLA2 
levels may be of a diagnostic significance.  
 
Geographical variation in the composition and potency of venom proteins with 
specific reference to PLA2 
There is considerable variation in the composition of different venom proteins in different 
parts of India. Venoms of Russell’s viper in north and western India showed presence of  
3 protein bands with molecular weight of 9000, 39,000 and 66,000 in the SDS 
PAGE(Sodium dodecyl sulphate/polyacryl gel electrophoresis) which were absent in the 
South Indian species. The phospholipases were acidic in the north and western snakes 
and was alkaline in the South Indian species. Higher phospholipase activity had 
correlation with higher lethal potency.(56) 
The venom of naja naja species has different biochemical and pharmacological 
properties in different regions of India. It was observed that there was a high mortality 
associated with the cobra bites in Eastern India despite giving adequate antivenom. It was 
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postulated that the variations in the toxicity and lethality of cobra bites were due to the 
variations in the peptides and phospholipase A2 in different areas. There was proven 
organ specific toxicity differences with more vasculotoxicity and myotoxicity in mice 
models of the venom of Naja naja obtained from Eastern India when compared to 
Southern and Western India.(57) The variation in envenomation and potency was further 
explained by mass spectrometry analysis which showed absence of 12kDa, 24 kDa and 
33 kDa peptides in the venoms obtained from South India and the presence of a 6.7 kDa 
peptide which was found exclusively in the venom obtained from Eastern India.(58) There 
is also considerable variation in the phospholipase A2 fractions which are not fully 
characterized as well as the three finger toxins in the venom of cobra species.(59) 
 
PLA2 in the serum and its diagnostic utility in systemic envenomation 
Most of the diagnostic tests in snake envenomation currently used are indirect methods of 
organ sytem injury caused by snake bites like coagulopathy, neurotoxicity and renal 
failure. The disadvantage of these tests is that they are generally detected after the 
establishment of systemic envenomation. There is a need to establish a diagnostic test 
which is based on the detection of venom proteins of the snake which could predict 
systemic envenomation. PLA2 is present in viperidae and crotalidae families which 
makes it really significant in Indian setting where the species of these families constitute 
most of the envenomation.(47)  
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A good diagnostic test for snake bite should have the following characteristics: (a) good 
sensitivity and specificity, (b) cost effectiveness, (c) point of care bedside test.  
Maduwage et al, showed that there was a statistically significant difference in the PLA2 
activity in the subjects with snake bite and systemic envenomation when compared to 
their non envenomated counterparts.  The maximum PLA2 activity was seen for 
Russell’s viper envenomation (median-55.7 μmol/ml/min), mild increase was noted for 
hump nosed pit viper (median-13.6 μmol/ml/min), cobra (median-14.8 μmol/ml/min), 
krait (median-17.2 μmol/ml/min) compared to (median-6.0 μmol/ml/min) in non 
envenomated samples.(47) 
 
Elevated PLA2 and associated medical conditions 
PLA2 is normally essential for the integrity of cell membranes and is present in the serum 
in normal individuals. However, it is also an acute phase reactant protein and becomes 
elevated in certain medical conditions.  PLA2 activity is increased in sepsis, pancreatitis, 
pancreatic acinar cell tumors, peritonitis, multiple injuries, rheumatoid arthritis and other 
arthropathies, malignancies, complications of pregnancies and post-operative states.(60) 
Enzymatic tests for PLA2 do not distinguish between the different PLA2 enzymes and 
between human and snake venom PLA2. Local inflammation and organ system 
dysfunction in snake bite could also contribute to increased endogenous PLA2 levels. 
Hence it is not clear if PLA2 can be used a diagnostic test for snake bite..  PLA2 can 
cause renal injury but the mechanism is unclear. It is proposed that there is accumulation 
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of lysophospholipids and long chain acyl carnitines and long chain acyl coenzyme A 
which is produced by the increased catalytic activity of phospholipase A2 in ischemic 
renal injury which inhibit  Na+K+ ATPase of the proximal tubule resulting in renal 
injury.(61) PLA2 can be elevated in kidney disease. Primary membranous nephropathy is 
another condition where higher levels of antibodies to phospholipase A2 receptors were 
associated with higher disease activity. (62) PLA2 can be cause and consequence of renal 
injury. The significance of elevation of PLA2 in snake bite related renal injury is unclear.  
 
Immunological diagnostic tests 
The principle behind immunological tests is that the venom antigen in the serum is 
coupled with a known antibody and the extent of antigen antibody complex formation is 
detected by using an enzyme linked to the known antibody which produces a colour 
change. The use of ELISA (enzyme linked immunosorbent assay) has been attempted in 
the detection of snake venom antigens in the serum. However there has been cross 
reactivity, non specific reactivity and variation in the quality of reagents that were used 
which hindered the bedside applicability of these tests.(63) Subsequently, ELISA tests 
were developed against the venom antigens of the Big 4 snakes of India which was used 
to identify the venom present in the tissues of autopsy patients who died of snake bite.(64) 
In Australia, a snake venom detection kit was designed to detect the presence and type of 
specific venom protein of the poisonous species of snakes. The best method was sample 
collection from the bite site and the kit could identify nanogram quantities of venom. If 
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bite site was not identified, then blood or urine was used in patients with systemic 
envenomation.  If dead snake is available, a swab from the fangs may yield a positive 
result.(65) This test is used in the field to diagnose snake bite in the field and to guide 
monovalent antivenom use. No other country presently uses venom detection tests for 
diagnosis of snake bite. 
3 DNA diagnosis from the bite swab 
Attempts have been made to diagnose biting species PCR-aided DNA sequencing from 
swabs of bite sites. This is a useful research tool but has low yield and is costly.(66) 
Characteristics of a good diagnostic test 
Currently there is no diagnostic test for systemic envenomation based on venom protein 
detection. A good diagnostic test in snake bite has to be 
Rapid  
Reliable diagnosis of envenomation 
Bed side point of care testing 
Enable Biting species diagnosis 
Cost effective  
Should not be altered by ASV administration (47) 
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Problems in the development of diagnostic test for snake envenomation in Indian 
setting 
Currently the diagnosis of snake envenomation in India is based on clinical assessment 
and monitoring of systemic envenomation for haemotoxicity and neurotoxicity, 
20WBCT/PT/APTT for the diagnosis of venom induced consumptive coagulopathy and 
monitoring of urine output and renal parameters for the incidence of complications. 
These factors largely determine the decisions on ASV administration in patients with 
systemic envenomation. There is no laboratory diagnostic test identified that predict 
systemic envenomation before the incidence of complications in snake envenomation that 
could facilitate early administration of ASV. 
There is geographical variation in the prevalence of snake species across India. There is 
also variation in envenomation syndromes of each snake species across geographical 
regions due to variability in the composition of venom proteins. This makes it difficult to 
formulate a diagnostic test based on venom proteins that is effective in diagnosis of snake 
envenomation all over the country. Hence there is a need for diagnostic tests formulated 
based on the regional prevalence of different snake species and envenomation patterns. 
The enzymatic assays do not distinguish endogenous and exogenous proteins.  Cross 
reactivity between human proteins and venom proteins poses difficulty for immune 
diagnosis. The concentration of venom proteins in the serum is very low and hence the 
tests need to be very sensitive.  
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Various attempts at Christian Medical College have been made to detect venom proteins 
based on immunostaining for secondary antibodies in the serum on ASV coupled 
columns and SDS-PAGE (Sodium dodecyl sulphate-Polyacrylamide gel electrophoresis). 
The venom proteins could not be successfully detected in these attempts due to the low 
concentration of venom proteins in the serum and the cross reactivity of the venom 
proteins with human serum proteins and ASV.(unpublished data). 
The review of literature highlights the need for developing a snake bite diagnostic test as 
well as the problems in developing such a test. The present study is to evaluate the role of 
PLA2 enzyme level in diagnosis of snake envenomation. 
 
Lacunar knowledge and justification 
(1) Clinical study of snake envenomation syndromes in Tamil Nadu 
There has been considerable geographical variation in the envenomation syndromes 
across different regions of India. This is partly attributed to the geographical variation in 
snake species as well as the regional variations of venom proteins within a snake species. 
The information on the local envenomations syndromes in Tamil Nadu is limited where 
there is predominance of Viperidae bites and specifically Russell’s viper envenomation. 
Russell’s viper envenomation has been noted to have high rates of complications 
including haemotoxicity in combination with acute kidney injury and neurotoxicity 
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leading to mortality. Hence it is essential to understand the patterns of envenomation in 
South India and the response to antivenom.  
(2) Serum PLA2 as a diagnostic test for snake envenomation 
The diagnostic utility of PLA2 has been documented in a previous study by Maduwage et 
al. The utility of this test needs evaluation in the Indian setting.  
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Materials and Methods 
The study protocol was defined at the beginning of the study and was approved by the 
Institutional Review Board (IRB). In view of the difficulties in isolating the venom 
proteins, an addendum was added to assess the diagnostic and prognostic utility of a 
specific protein Phosholipase A2 which was also approved by the IRB.  
This is a descriptive single center study done in patients above the age of 15 who present 
to Emergency Department  of our hospital with history of snake bite/ unknown bite with 
typical envenomation syndromes.  Informed consent was taken from the patient/relatives 
at the start of recruitment.   
Patient population: 
Snake envenomation 
Inclusion criteria 
Patients who presented to Emergency Department of CMC Vellore with alleged 
history of snake bite with envenomation syndromes at presentation or at a later 
stage and also in patients with suspected envenomation syndromes without the 
history of bite or bite marks who had been noted to have treatment response with 
antisnake venom from September 2014 to January 2016.  
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 All patients above the age of 16 years with informed consent by the patient or the 
relatives (if the patient is unconscious/sedated)(informed assent from caretakers if 
16-18 years of age) will be recruited in the study.  
Exclusion criteria 
 Patients who had not given informed consent, paediatric age group(<15 years), 
patients who are brought dead to triage with alleged history of snake bite or 
envenomation syndromes, patients admitted with snake bite with no signs of 
envenomation syndromes after observation for 24 hours will be excluded from the 
study. 
Snake bite without envenomation- snake bite without evidence of local or systemic 
envenomation.Since the number of non-envenomated snake patients coming to our center 
was less, the non envenomated control samples (n=64) were obtained after informed 
consent of the patient/relatives from Government Vellore Medical College. 
Normal healthy controls for PLA2 measurement- 30 staff and student at CMC Vellore 
Exclusion criteria: All patients/relatives who did not provide consent and pregnant 
women were excluded from the study. 
Detailed clinical assessment was done by the principal investigator to assess the 
envenomation syndromes at admission and on a daily basis till the discharge or for 5 days 
whichever is earlier.   
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Blood samples: The venous samples were collected every day from admission for a 
maximum of 5 days depending upon the duration of stay of the patient. The samples were 
immediately refrigerated at <4 degree Celsius. The serum is isolated after centrifugation 
and analysed for the levels of PLA2.  
The outcome was assessed by the mortality, incidence of various envenomation 
syndromes and its duration of persistence after the administration of ASV incidence of 
complications like renal injury, venom induced consumptive coagulopathy, requirement 
of product support like Fresh frozen plasma and cryoprecipitate to neutralize the 
coagulopathy. 
Definition of envenomation syndromes 
Local envenomation 
Local swelling in the absence of a tourniquet 
 Enlarged tender lymph node draining the bitten limb 
Necrosis, blistering 
Necrotising fascitis 
Compartment syndrome –absent pulses 
Gangrene 
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Haemotoxicity 
Hemorrhagic manifestations (systemic bleeding menifestations) or 
Whole blood clotting test › 20 minutes with a clean dry new test tube, never reuse the 
test tube.  
      Deranged PT/PTT (INR >1.2 or PT prolonged by more than 4-5 seconds) 
Platelet count <100,000 cells/mm3   
Neurotoxicity- (any of the below) 
 Ptosis or Opthalmoplegia, neck muscle weakness, bulbar weakness – dysphagia, 
difficulty in speaking, inability to protrude the tongue beyond the incisors 
 Limb muscle weakness grade 4 or less 
 Respiratory paralysis-Reduced single breath count<10, paradoxical breathing / Type 
2 respiratory failure/need for mechanical ventilation, respiratory arrest at presentation 
 Definition of Renal failure- RIFLE/AKIN criteria 
The RIFLE criteria is used for the diagnosis of AKI in snake bites. This is as follows 
Risk – 1.5-fold increase in the serum creatinine, or glomerular filtration rate (GFR) 
decrease by 25 percent, or urine output <0.5 mL/kg per hour for six hours 
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Injury – Twofold increase in the serum creatinine, or GFR decrease by 50 percent, or 
urine output <0.5 mL/kg per hour for 12 hours 
Failure – Threefold increase in the serum creatinine, or GFR decrease by 75 percent, or 
urine output of <0.3 mL/kg per hour for 24 hours, or anuria for 12 hours 
Loss – Complete loss of kidney function (eg, need for renal replacement therapy) for 
more than four weeks 
ESRD – Complete loss of kidney function (eg, need for renal replacement therapy) for 
more than three months 
 
The AKIN diagnostic criteria for AKI specify an abrupt (within 48 hours), absolute 
increase in the serum creatinine concentration of ≥0.3 mg/dL (26.4 micromol/L) from 
baseline; a percentage increase in the serum creatinine concentration of ≥50 percent; or 
oliguria of <0.5 mL/kg per hour for more than six hours. 
Impending AKI signalled by abrupt reduction in kidney function over 48 hours: 
decreasing/no urine output, increased/increasing serum creatinine concentration, clinical 
―uraemia syndrome‖ (nausea, vomiting, acidotic breathing, hiccups, fetor, drowsiness, 
confusion, coma, flapping tremor, muscle twitching, convulsions, pericardial friction rub, 
signs of fluid overload). Patients with any of these features should be monitored for other 
clinical signs of ―uraemic syndrome‖, pulse rate, postural blood pressure, height of 
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jugular venous pulse, respiratory rate, temperature, auscultation of lung bases for 
crepitations, fluid balance chart and/ or daily weight. 
Most patients with AKI become oliguric (urine output < 400 ml/day or < 30 ml (children 
<0.5ml/kg bodyweight /hour). 
 
Cardiac toxicity 
Cardiac involvement has been described for viperdae bites and involves visual 
disturbances, dizziness, faintness, collapse, shock, hypotension, cardiac arrhythmias, 
myocardial damage. 
Cardiac involvement is studied with serial Blood Pressure monitoring, ECG and 
Echocardiography if there are clinical signs of congestive cardiac failure. 
Generalised increase in capillary permeability is manifested as facial, periorbital, 
conjunctival oedema (chemosis), bilateral parotid enlargement, pleural and pericardial 
effusions, pulmonary oedema, massive albuminuria and haemoconcentration. 
 
Antivenom reactions 
Antivenom reactions are classified into 3 categories.  
1. Early anaphylactic reactions occur characteristically within 180 minutes of the 
start of the antivenom. It can have diverse manifestations like itching, urticaria to 
bronchospasm, shock and angioedema.  It is mediated by complement activation 
by IgG or Fc segment of the immunoglobulins of the antivenom. 
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2. Pyrogenic reactions occur within 1-2 hours after the start of ASV characterized by 
fever with chills, rigors, fall in BP and shock due to vasodilation. The pyrogen 
contamination during the manufacture is attributed as the probable cause. 
3. Late serum sickness to ASV occurs after a week of ASV administration 
characterized by fever, nausea, vomiting, diarrhoea, itching,  recurrent urticaria, 
arthralgia, myalgia, lymphadenopathy, periarticular swellings, mononeuritis 
multiplex, proteinuria, immunecomplex nephritis and occasionally 
encephalopathy. 
Treatment variables that were assessed 
Local measures-tourniquet, pressure immobilisation 
Antibiotics 
Anti-snake venom dose 
 Total dose administered to patient including dose administered in outside hospital  
Adrenaline/hydrocortisone 
Neostigmine 
Ventilation /bagging 
Dialysis requirement 
Transfusion requirement and blood product support 
ICU care 
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Treatment outcomes 
Haemotoxicity 
Time to normalisation of CT or PT/PTT 
Neurotoxicity 
Time to regaining normal power (except respiratory muscle weakness) 
Time to extubation 
Allergic reactions 
Minor-itching, urticaria, wheals 
Major-angioedema, anaphylactic shock, death 
Mortality 
Need for surgical debridement or amputation 
Outcome of the patient- discharge/death/discharged against medical advice 
Mortality analysis based on (1) pathophysiology leading to death; (2) Death as a result of 
complication of snake bite; (3) Anaphylaxis; (4) Deaths unrelated to snake bite. 
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  Methodology of PLA2 assay 
Sample Preparation 
Envenomated and non-envenomated serum samples were diluted in the ratio of 1:100 
using NOBA buffer contains 100 mM Tris, 10 mM Cacl2, 0.1 M Nacl pH 8.0.  
Assay Procedure 
PLA2 activity was assayed on the chromogenic substrate 4-Nitro-3-ocatanoyloxy benzoic 
acid (NOBA). 
Twenty five µl (25 µl) of each diluted serum samples were mixed with 200 µl NOBA 
buffer contains 100 mM Tris, 10 mM Cacl2, 0.1 M Nacl pH 8.0 and 25 µl of NOBA 
substrate with final substrate concentration of 0.3 mM. 
Then the plates were incubated at 37 ˚c for 60 min, and absorbance was recorded at 405 
nm in ELIZA reader.  
Validation of the optical density values  
All the samples were assayed in triplicates and the mean value obtained in optcal density 
was taken for analysis. If there was high variation in the 3 values, the assay was repeated 
again in triplicates and the mean value was taken for analysis.  
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Flowchart 
 
 
Figure 3- 
flowchart
 
The optical density values obtained is converted to s PLA2 activity using the following 
formula 
sPLA2 Activity (µmol/min/ml) = OD x 0.200 ml x Sample dilution /10.66 X 0.01 ml 
4-Nitro-3-
ocatanoyloxy benzoic 
acid(NOBA) 
3-hydroxy-4-
nitrobenzoic acid 
PLA2 
25 µl of sample 
Mixed with 200 µl of buffer contains 100 
mM Tris, 10 mM Cacl2, 0.1 M NaclpH 8.0 
25 µl of NOBA 0.3 mM 
Incubate plate @ 37 ˚c for 60 min 
Measure the absorbance at 405 nm 
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10.66 is the extinction co-efficient of the bi product (DTNB) 
0.200 ml is the volume of the reaction mixture 
sample dilution = 100 
0.01 ml is the sample volume 
Analysis of the clinic-laboratory correlation of snake bite with PLA2 levels 
The PLA2 levels in serum were measured at admission in Optical density using 
spectrophotometry. It was done for 100 patients with systemic envenomation and 64 non 
envenomated controls (Patients with snake bite without systemic envenomation). The 
PLA2 values in μmol/min/ml was obtained by multiplying the optical density values with 
a constant 187.62 based on the dilution used in the lab and the volume of serum. 
 
Sample size calculation 
As per the Australian Snake Bite study Project 11, which was a study aimed to 
correlate the venom proteins in the serum with the clinical profile of snake bite patients, 
considering the incidence of coagulopathy  as 61% among the patients with systemic 
envenomation syndromes in red bellied black snake bite, with precision of 10% and 
confidence interval 95%, the sample size calculated was   92 . 
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Type of data and method of analysis 
The principal investigator fills up a questionnaire containing history, demographic 
details, clinical examination findings with the treatment details at admission and daily for 
a period of 5 days or till discharge.  The phospholipase activity is measured on the serial 
serum samples taken as mentioned in the methodology.  
The data was analyzed using simple descriptive methods such as frequencies, box 
plot, histograms etc to screen for outliers and data validation (ranges etc). The prevalence 
of overall mortality rate was presented with 95% CI. Similarly the incidence of 
syndromes was  presented with 95% CI as overall. . The correlation/association between 
syndromes, socio demographic variables and mortality, complications was done using 
chi-square test and also was presented with Relative Risk with 95% CI. The correlation 
between various envenomation syndromes and the phospholipase A2 in serum at 
admission was analysed using tests of significance like p value comparing it to the PLA2 
levels in non envenomated controls. The relation of incidence of complications and the 
admission PLA2 levels was assessed for significance using p values among envenomated 
patients.   
Funding and approval 
The protocol and the amendment were approved by the institutional review board and the 
funding was provided by the FLUID grant of the IRB. 
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Results 
The clinical assessment and documentation was carried out for a period of 2 years from 
February 2014 to January 2016. 167 patients fulfilled the inclusion criteria and were 
enrolled for the study after obtaining informed consent.  
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STROBE FIGURE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-STROBE figure 
 
231 patients recruited for the 
study  
73,343 patients coming to 
Emergency Department 2015-
2016. 
273 patients presented to Emergency 
Department with alleged history of 
snake bite/unknown bite with 
envenomation syndromes (Feb 
2014- Jan2016) 
42 patients refused 
consent and hence 
excluded. 
64 patients with no 
envenomation syndrome 
(controls)(obtained from 
Government medical 
college) 
167 patients with systemic 
envenomation for clinical 
assessment 
Venous samples were collected 
for 100 patients with systemic 
envenomation for PLA2 activity 
assessment (September 2014-
January2016) (cases) 
Venous samples were 
collected for the assessment of 
PLA2 activity (controls) 
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STRUCTURE OF RESULTS SECTION 
 
SECTION I- CLINICAL PROFILE OF SNAKE ENVENOMATION 
Demography of patients (Figure 5) 
The median age of the patients was 36 years (15-68). Two thirds of the affected were 
males. Agricultural labourers constituted majority of the population (64%) followed by 
construction labourers including masons (21%) followed by housewives. 
 
Figure 5 Snake bite- sex distribution 
Site of bite (Figure 6) 
Most of the bites were in the lower limbs. Right side upper and lower limbs had slightly 
higher bites compared to left side. There were 2 patients who had typical envenomation 
syndromes of snake bite but the bite site could not be identified. These patients had pure 
neurotoxicity. 
67%
33%
Sex
Males Females
n= 57
n=110
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Figure 6- Distribution of site of snake bite 
 The time delay from snake bite to ASV 
The median time gap between snake bite and ASV administration was 4 hours (range 1-
185 hrs). There were 12 cases where the time lapse between first ASV dose and 
admission was not available.  
Abdominal pain in Russell’s viper envenomation 
The incidence of abdominal pain in Russell’s viper envenomation was 15.83% n=19.  In 
patients with Russell’s viper envenomation with abdominal pain at presentation, 84.2% 
n=16 developed VICC, 78.9% N=15 developed neurotoxicity and 63.2% N=12 
developed AKI. 
 
 
Distribution of various envenomation syndromes in snake bite patients (Table 5) 
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The categorisation of syndromes was based on the WHO South East Asia Guidelines 
(2016) (See Review of literature). Russell’s viper bite syndromes include haemotoxicity 
or haemotoxicity in combination with neurotoxicity and/or acute kidney injury. Pure 
haemotoxicity could either be due to Saw Scaled viper bites or Russell’s viper. Krait bite 
syndrome causes neuroparalysis without local swelling and may have associated 
abdominal pain. Cobra bite syndrome causes neuroparalysis with local swelling. 
  
There were 3 patients (1.79%) with no envenomation and 6 patients (3.58%) with local 
envenomation. There were 26 patients (15.57%) with local swelling and haemotoxicity 
(probably Saw scaled viper or Russell's viper envenomation). There were 102 patients 
with combinations of haemotoxicity with neurotoxicity and/or acute kidney injury (61%) 
(which were probably due to Russell's viper envenomation). The most common Russell's 
viper syndromes were haemotoxicity with neurotoxicity and haemotoxicity with 
neurotoxicity and acute kidney injury. There 12 cases (7.2%) with neurotoxicity without 
local swelling (probable Krait bite) and 18 cases (10.8%) with neurotoxicity with local 
swelling (probable cobra bite). All the deaths occurred in the syndromes of Russell’s 
viper with haemotoxicity with AKI. 
 Therefore in this study Russell’s viper is the most common species of snake responsible 
for systemic envenomation. The distribution of the patterns of envenomation is shown in 
Table 5. 
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Table 5- Snake envenomation syndromes 
Envenomation syndromes 
Pattern of 
toxicity 
Number 
of 
patients 
Percentage 
of patients 
Number 
of 
deaths 
No envenomation  3 1.79  
Local swelling only  6 3.58  
Haemotoxicity+local swelling 
Saw scaled 
viper or 
Russell’s viper 
envenomation 
26 15.57  
Haemotoxicity without local 
swelling 
 0 0  
Haemotoxicity+Neurotoxicity+local 
swelling 
Russell’s viper 
envenomation 
(61.07%) 
41 24.55  
Haemotoxicity+Neurotoxicity 
without local swelling 
3 1.79  
Haemotoxicity+Neurotoxicity+renal 
failure+local swelling 
43 26.06 3 
Haemotoxicity+renal failure+local 
swelling 
15 8.98 2 
Neurotoxicity only 
Common Krait 
bite  
12 7.19  
Neurotoxicity +local swelling 
Indian cobra 
bite  
18 10.78  
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Correlation of Envenomation Syndrome and identification of dead snake species (Table 6) 
Among the patients who brought the snake to the hospital, further identification of the 
snake species was carried out in Forensic Medicine Department with assistance from a 
trained herpetologist and was correlated with their clinical syndrome. 13 snakes were 
brought of which two were non-venomous. The syndrome species correlation were 
consistent with known literature: 
(a) Haemotoxicity with associated neurotoxicity and/or acute kidney injury syndrome 
– Russell’s viper envenomation 
(b)  Neurotoxicity in the absence of local swelling -Krait envenomation 
(c)  Neurotoxicity and local swelling - Cobra bites 
(d)  Haemotoxicity and local swelling- Saw scaled vipers presented 
There is absence of neurotoxicity and acute kidney injury in Saw scaled viper bite. 
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Table 6 Correlation of Envenomation Syndrome and identification of dead snake 
species  
Snake species identified Number Syndromes (n) 
Saw scaled viper(Echis carinatus) 2 
Local envenomation (1) 
Haemotoxicity+local envenomation (1) 
Russell’s viper (Daboia russelii) 4 
Haemotoxicity+neurotoxicity+local 
envenomation (2) 
Haemotoxicity+local cellulitis(1) 
Haemotoxicity+ AKI+ local 
enveomation(1) 
Indian Cobra (Naja naja) 3 
Local envenomation (1) 
Neurotoxicity + local envenomation (2) 
Common Krait (Bungarus 
caeruleus) 
2 
Neurotoxicity without local 
envenomation (2) 
Russell’s kukri 1 Local envenomation (1) 
Indian Wolf snake 1 No envenomation (1) 
Neurotoxicity in snake bite patients (Figure 7) 
The proportion of neurotoxicity in snake bite patients was 67.07% (n=112). The common 
neurological manifestations seen were ptosis and ophthalmoplegia. Severe neurological 
manifestations like respiratory muscle weakness including diaphragmatic paralysis, 
bulbar weakness and limb weakness were relatively less common (about 35%).  
The median duration of ptosis and ophthalmoplegia were 3 days (range 1-8 days) and 4 
days (range 2-10 days) respectively. The median duration of bulbar and respiratory 
muscle weakness was 2 days (range1-5 days). The occurrence of various manifestations 
of neurotoxicity in snake bite is outlined in Figure 8.  
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Figure 7- Frequency of individual muscle weakness in Snake bite  
 Differences in neuroparalysis spectrum (Table 7) 
Ptosis and opthalmoplegia occurred in the majority of both Russell’s viper envenomation 
and Elapidae syndromes. Russell’s viper envenomation syndrome was associated with 
lower frequency of bulbar, respiratory and limb weakness. 
The occurrence of ptosis and ophthalmoplegia did not differ between viperine 
envenomation and neurotoxic envenomation in the absence of haemotoxicity (krait and 
cobra bites) p>0.999. However the occurrence of respiratory muscle weakness and limb 
weakness were higher in krait and cobra envenomation compared to viperine 
envenomation with p=0.051 and p= 0.007 respectively. There was a trend to increased 
98.21%
77.68%
33.92%
35.71%
9.82%
0.00% 20.00%40.00%60.00%80.00%100.00%120.00%
Ptosis
Ophthalmoplegia
Respiratory muscle weakness
Bulbar weakness
Limb weakness
Frequency of individual muscle weakness in Snake bite
Incidence of different neurological 
manifestations
n=11
n=40
n=38
n=87
n=110
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occurrence of bulbar weakness in the krait/cobra group compared to viperine group 
although not statistically significant p=0.357. The occurrence of respiratory muscle 
weakness ( p=0.019)and limb weakness (p=0.0135)was significantly higher in krait 
envenomation than viperine envenomation as shown in table 7. 
The duration of neurotoxicity was measured as the time for complete resolution of any 
weakness. The neurotoxicity without local reaction as observed in the classical Krait Bite 
lasted for a median of 4 days (Range 3-7 days). The classical Russell’s viper 
envenomation which was very common in the area had neurotoxic manifestations lasting 
for a median of 4 days (Range 1-6 days). The neurotoxicity with cellulitis without 
haemotoxicity were rapidly reversible with ASV (probable cobra envenomation) with a 
median duration of 3 days (1-5 days).  
Table 7 Neuroparalysis spectrum in snake bite syndromes. 
Pattern of 
neurotoxicity 
Probable Russell’s 
viper syndrome 
(Haemotoxicity + 
Neurotoxicity) 
n (%)           Median  
                     duration         
Probable Krait bite 
(Pure 
neuroparalysis) 
  
n (%)          Median 
                 duration   
Probable Cobra Bite 
(Neuroparalysis 
+local swelling)  
 
n (%)            Median    
                  duration 
Ptosis 
81 
(98.78%) 
3 days 
12 
(100%) 
3 days 
17 
(94.4%) 
2 days 
Ophthalmoplegia 
63 
(76.82%) 
4 days 
10 
(83.3%) 
4 days 
13 
(72.2%) 
3 days 
Bulbar muscle 
weakness 
26 
(31.71%) 
2 days 6 (50%) 3 days 
7 
(38.9%) 
2 days 
Respiratory muscle 
weakness 
23 
(28.05% ) 
Not 
assessed 
8 
(66.67%) 
Not 
assessed 
7 
(38.9%) 
Not 
assessed 
Limb weakness 5 (6.1%) 2 days 
4 
(33.33%) 
3 days 
4 
(22.2%) 
1 day 
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Haemotoxicity in snake bites (Figure 8) 
Haemotoxicity was the most common manifestation of systemic envenomation due to 
snake bite occurring in 76.05% of the patients (n=127). Most of the cases presented at our 
centers had internal bleeding manifestations like hematuria, haematemesis and melaena 
(63.78%, n=81).  The most common manifestation of haemotoxicity was venom induced 
consumptive coagulopathy which occurred in 76.38% of the patients with haemotoxicity 
(n= 97). 66.1% of patients had thrombocytopenia. More than half of these patients had 
reversal of coagulation parameters with the administration of ASV. 35.43% (n=45) of the 
patients with haemotoxicity required product support for the normalization of coagulation 
parameters. The occurrence of various haemotoxic manifestations are as shown in figure 
8. 
 
Figure 8 Occurence of haemotoxic manifestations (denominator is the patients with 
haemotoxicity). 
70.87%
63.78%
66.14%
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35.43%
0.00% 20.00%40.00%60.00%80.00%100.00%
Bleeding manifestations
Internal bleeding
Thrombocytopenia
Venom induced consumptive 
coagulopathy
VICC requiring product support
Occurence of different haemotoxic 
manifestations
Incidence of different 
haemotoxic manifestations
n=45
n=97
n=84
n=81
n=90
62 
 
The median duration of haemotoxicity was 24 hours (6 hours to 5 days). It was seen that 
most of the patients had reversal of coagulation parameters and bleeding manifestations 
after the administration of ASV with in 1 day. Venom induced consumptive 
coagulopathy which required product support involving fresh frozen plasma and 
cryoprecipitate required longer duration for reversal of haemotoxicity. 
Acute Kidney Injury 
The incidence of acute kidney injury was 34.73% (n=58). Just more than half of the 
patients with acute kidney injury n=34 (20.36%) required haemodialysis and the rest 
showed resolution of renal functions without the requirement of renal replacement 
therapy. 14.97% (n=25) of the patients showed a triad of hemolytic anemia, 
thrombocytopenia and acute renal injury but the diagnosis of microangiopathic hemolytic 
anemia and hemolytic uremic syndrome was not established in most of them. Few 
patients underwent renal biopsies (n=3) the histopathology of which showed acute 
tubular necrosis. Rhabdomyolysis as defined by muscle injury with elevation in the CPK 
levels more than 5 times the upper limit of normal (>975 IU/ml)(67) was seen in 26.41% 
of the patients(n=34) Most of the patients were lost to follow up after the discharge but 
among the patients (n=10) who came for review, there was resolution of renal function to 
normal levels with a median duration of 90 days. 
Muscle injury following snake bites 
Muscle injury was diagnosed if the patient developed severe muscle pain or elevated 
CPK more than 5 times the normal (CPK>975 IU/ml). 47 patients out of 132 (35.6%) 
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developed myotoxicity among total patients with snake bite. In Viperidae bites, 44.85% 
developed muscle injury (n=48). In patients with Russell’s viper syndrome, muscle injury 
was documented in 45.05% ( n=41). In patients with pure haemotoxicity, muscle injury 
was documented in 43.75% (n=7). Among the patients who developed AKI, 48.39% 
(n=30) had features of rhabdomyolysis. The incidence of muscle injury in Krait and cobra 
bites were 8.33% (n=1) and 5.55% n=1 respectively. 
Local envenomation 
88.02% (n=147) had local envenomation associated with swelling at the bite site. Most of 
them (82.03%, n=137) had swelling tenderness and redness with probable cellulitis 
requiring antibiotics.  The incidence of necrotizing fasciitis requiring debridement and 
fasciotomy was 7.78% (n=13). 
Anti-snake venom (ASV) (Figure 9) 
About three fourth of the patients (75.45%, n=126) who presented to CMC had received 
ASV from outside. Most of them had received liquid ASV with a median dose of 8 vials 
(Range 1-30).  The median total ASV vials given per patient was 16 (range 2-45). One 
third of the patients (33.54%, n=54) who received ASV had some form of 
hypersensitivity reaction. The frequency of hypersensitivity reactions were: itching 
(94.54%),  urticaria (74.55%) , anaphylaxis (29.09%) and bronchospasm (36.36%) (see 
figure 9). 
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Figure 9 Frequency of hypersensitivity reaction to ASV  
(The denominator is the number of patients who developed ASV hypersensitivity n=54) 
 
ASV dose requirement in different envenomation syndromes 
Russell’s viper envenomation syndrome required maximum ASV for reversal of toxicity 
with median of 18 vials in comparison to pure hemotoxicity of 14 vials, Krait bite 
syndrome of 13.5 vials and Cobra bite syndrome of 11 vials.  
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Table 8 summarises the ASV dose requirement in different envenomation syndromes. 
Envenomation syndrome Median ASV dose in vials Range 
Russell’s viper 18 (0-44) 
Pure haemotoxicity (Saw 
scaled/Russells viper) 
14 (9-30) 
Viperine envenomation 17 (0-44) 
Krait 13.5 (10-22) 
Cobra 11 (5-32) 
 
The median ASV requirement in Elapidae bites at our center was 12.5 vials (5-32) and 
that of Viperidae bites were 17 vials. This difference was statistically significant 
(p=0.002).  
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Figure 10 showing the increased requirement of ASV for Viperine syndrome compared to 
Elapidae bites 
 
 The patients with Russells viper envenomation required higher dose of ASV when 
compared to patients with pure haemotoxicity. (p=0.012) 
67 
 
 
Figure 11 showing higher requirement of ASV in Russells viper envenomation when 
compared to pure haemotoxicity. 
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ICU stay and duration of mechanical ventilation 
Most of the patients who presented to out center were referred cases and 40.11% (n=67) 
of them required ICU admission. The indications for ICU admission were mechanical 
ventilation, inotropic support requirement and renal replacement therapy/ plasmapheresis. 
The median duration of mechanical ventilation was 4 days (range1-21 days). The most 
common complication among the patients admitted in ICU was sepsis, most frequently 
due to ventilator associated pneumonia.  
Unusual manifestations associated with snake bite 
Myocarditis and cardiogenic shock 
Myocarditis with cardiogenic shock has been described in the literature as a result of 
direct toxicity of the venom proteins.  It has been associated with poorer outcome in view 
of the shock and associated with higher mortality rates.(22) 5.98% (n=10) of the patients 
had clinical signs of cardiac failure and evidence of cardiogenic shock with ECHO 
showing LV dysfunction and elevated cardiac enzyme levels suggestive of myocarditis. 
Myocarditis with LV dysfunction was most commonly seen associated with Russell’s 
viper envenomation (7.84%, n=8). There was one case of transient myocarditis associated 
with pure haemotoxicity syndrome and one with cobra bite.  
Cerebrovascular accident 
There were 3 patients (1.79%) who developed cerebrovascular accident during their stay 
in hospital after snake bite. 2 cases had multiple infarcts in the cortex with permanent 
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residual neurological deficits and the outcome was poor. The third case developed a left 
cerebellar bleed with mass effect. This patient improved with medical management and 
did not require neurosurgical intervention.  
Hypopituitrism 
There were 2 (1.2%) cases of Hypopituitrism developing secondary to snake bite both of 
which had viperine manifestations associated (neurotoxicity and haemotoxicity). 
Hypopituitrism syndrome was confirmed by decreased hormonal levels suggestive of 
pituitary hypofunction in both the patients and MRI showing pituitary hemorrhage in one 
of them.  
Other unsual manifestions of snake bite 
There was one case of acute pancreatitis developing after snake bite associated with 
shock liver and another case of acute angle closure glaucoma post snake bite.  
Outcome of patients (Figure 12) 
There were 5 deaths with snake bite at our centre over the 2 years of the study with a 
mortality rate of 2.99%. Three patients were discharged against medical advice (1.8%). 
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Figure 12- Outcome of patients with snake bite 
 Mortality analysis (Table 9) 
There were 5 patients (2.99%) who died during their stay in the hospital. We observed 
that the combination of VICC, AKI, rhabdomyolysis and cellulitis were present in all of 
the patients who died. Table 2 highlights the common features which were present in the 
patients who expired in the hospital. Nearly all the patients died in the 2
nd
 week due to 
late complications. 
Table 9- Envenomation features associated with mortality 
Patients Haemotoxicity Neurotoxicity Cellulitis 
Renal 
Injury 
Rhabdomyolysis 
Septic 
shock 
Duration 
A + + + + + + 7 days 
B + - + + + + 12 days 
C + - + + + - 11days 
D + + + + + + 14 days 
E + + + + + + 2 days 
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SECTION II- PLA2 LEVELS IN SNAKE ENVENOMATION 
 
PLA2 levels were measured in 30 normal controls, 100 patients with snake envenomation 
and 64 snake bite patients with no envenomation. 
Normal PLA2 activity in healthy controls 
The mean PLA2 in 30 healthy controls was 62.57± 13.34 μmol/min/ml and the median 
PLA2 activity was 62.10 μmol/min/ml (41.9-91.1). This assay could not distinguish 
exogenous venom PLA2 and endogenous human PLA2,  
Admission PLA2 levels and snake envenomation (Figure 11 and 12) 
 The median PLA2 activity at admission was 74.02 μmol/min/ml (40.2-180.6) for 
patients with systemic envenomation and 80.93 μmol/min/ml (40.9-151.6) in patients 
with snake bite without systemic envenomation and this difference was not significant 
(p=0.886). There were overlapping ranges with lower values of PLA2 found in both 
snake envenomation and non envenomated controls. The graph shows that higher values 
of PLA2 occurred only in systemic envenomation. 
 
 
72 
 
 
Figure 13 represents the box plot of the PLA2 values (median values with IQR) in 
systemic envenomation and patients with snake bite without any systemic envenomation.  
The median PLA2 activity in patients with systemic envenomation, 74.02 μmol/min/ml 
(40.2-180.6) was significantly higher than normal controls 62.10 μmol/min/ml (41.9-
91.1) (p=0.002).  
 
. 
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Figure 14 showing the box plot of PLA2 values highlighting the median with IQR for 
normal healthy controls and patients with systemic envenomation. 
 
 
 
74 
 
Relationship of  PLA2 to specific snake bite related envenomation syndromes 
(Table 10) 
This was done to assess whether PLA2 activity at admission could enable species specific 
diagnosis of snake envenomation in patients who developed systemic envenomation. 
Snake identification was limited to a few cases and hence it was decided to correlate 
PLA2 activity with species specific envenomation syndromes that were documented in 
envenomated patients.  
Table 10  PLA2 activity in different envenomation syndromes 
Envenomation 
syndrome 
Probable snake 
species 
implicated 
No of 
subjects 
Median PLA2 activity in  
μmol/min/ml(IQR) 
Pure haemotoxicity 
Russell’s/Saw 
scaled viper 
16 74.77 (66.18-103.02) 
Haemotoxicity+local 
reaction with 
neurotoxicity and/ or 
AKI 
Russell’s viper  63 79.86 (59.41-130.97) 
All haemotoxic bites  Viperidae  79 79.61(63.6-120.1) 
Neurotoxicity 
without local 
swelling 
Krait 9 61.79 (53.1-65.3) 
Neurotoxicity+local 
swelling 
Cobra 12 60.8 (53.2-78.0) 
Pure Neurotoxicity 
(without 
haemotoxicity) 
Krait/Cobra 21 61.78 (53.22-70.39) 
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Comparison of PLA2 in different species specific envenomation syndromes (Figures 15-18) 
 
1. Viperine envenomation with Elapidae bites (Krait /Cobra envenomation) (Figure 
13 
It was noted that the admission median PLA2 values were higher for Viperine 
envenomation 79.61(IQR 63.6-120.1) μmol/min/ml when compared to Elapidae 
(Krait/Cobra) envenomation. 61.78 (IQR 53.22-70.39) μmol/min/ml and this 
difference is statistically significant (p=0.001). 
The diagnostic utility of admission PLA2 in distinguishing between Viperine and 
Elapidae bites was examined using ROC curves (See Figure 14). The area under the 
curve was 0.743. A PLA2 level > 79.33 μmol/min/ml distinguished between Viperidae 
and Elapidae envenomation with a sensitivity of 50 % and specificity of 87.3%. 
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Figure 15 Comparison of admission PLA2  levels in Viper and Elapidae 
envenomationFigure demonstrating the box plot of PLA2 activity in Viperine versus 
Krait/Cobra envenomation. 
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ROC CURVE FOR PLA2 ACTIVITY TO DISTINGUISH VIPERIDAE AND 
ELAPIDAE ENVENOMATION 
 
Figure 16 demonstrating the Receiver Operator Characteristic Curve for predicting 
Viperine envenomation when compared to Elapidae bites using PLA2 levels. The area 
under the curve is 0.743. Values of PLA2 above 79.33 μmol/min/ml can distinguish 
Viperidae envenomation from Elapidae with a sensitivity of 50 % and specificity of 
87.3%. 
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2. Comparison of pure hemotoxic envenomation syndrome and classical Russell’s viper 
envenomation (Figure 17) 
The PLA2 levels in pure hemotoxic syndrome was 74.77 (66.18-103.02) μmol/min/ml 
and in Russell’s viper syndrome was  79.86 (59.41-130.97) μmol/min/ml and there no 
statistically significant difference (p=0.971). 
 
 
Figure 17 Comparison of admission PLA2 level in pure hemotoxic syndrome and 
classical Russell’s viper syndrome 
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Figure showing the box plot of PLA2 activity in patients with Russell’s viper 
envenomation with pure haemotoxicity. 
3. PLA2 activity in Krait versus Cobra envenomation (Figure 18) 
The median PLA2 acitivity in Krait envenomation syndrome was 61.79 (IQR 53.1-65.3) 
μmol/min/ml and in Cobra envenomation syndrome was 60.8 (IQR 53.2-78.0) 
μmol/min/ml (p=0.602). 
  
Figure 18  demonstrating the box plot of PLA2 activity with median and IQR in Krait and 
cobra envenomation. 
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Relationship of PLA2 to the severity of snake envenomation (Figure 19-22) 
1. PLA2 acitivity and product support requirement in Viperine envenomation(All 
.haemotoxic bites) (Figure 17) 
The admission PLA2 activity was assessed for predicting the severity of haemotoxic 
envenomation in viperine bites. In patients with haemotoxicity whose coagulation 
parameters got reverted with ASV alone, the admission median PLA2 activity was 72.80 
(IQR 59.4-90.8) μmol/min/ml. In patients who required ASV and product support for 
reversal of coagulopathy, the median admission PLA2 activity was 106.89 (69.7-144.8) 
μmol/min/ml.  This difference was statistically significant (p=0.009). 
The prognostic utility of admission PLA2 in predicting severe viper envenomation 
requiring transfusion was evaluate using ROC curve (Figure 18). The area under the 
curve was 0.751.  A PLA2 activity > 88.02 μmol/min/ml predicted requirement of 
product support with a sensitivity of 63% and a specificity of 84%. 
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Figure 19 showing box plot of PLA2 activity with median and IQR in patients with 
severe haemotoxicity who required product support and those whose haemotoxicity got 
neutralised with ASV alone. It is noted that the admission PLA2 activity was higher in 
the patients who required product support. 
 
 
 
 
 
82 
 
ROC CURVE TO PREDICT PHOSPHOLIPASE A2 ACTIVITY TO PREDICT 
SEVERE HAEMOTOXICITY (PRODUCT SUPPORT REQUIREMENT) 
 
 
 Figure 20 showing the ROC curve for PLA2 values to predict the product support 
requirement. Area under the curve is 0.751. PLA2 activity above 88.02 μmol/min/ml 
predicts requirement of product support with a sensitivity of 63% and a specificity of 
84%. 
2. PLA2 activity and viper envenomation with AKI requiring dialysis and no dialysis 
(Figure 21) 
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The admission PLA2 activity was assessed to predict the severity of acute kidney injury 
in Russell’s viper envenomation. Patients who went on to require haemodialysis were 
considered to have severe envenomation when compared to patients whose renal 
parameters improved with ASV alone. The median PLA2 activity in patients with AKI 
who required haemodialysis was 106.89 (IQR 74.33-146.92) μmol/min/ml when 
compared to 70.36 (IQR 59.2-92.0)μmol/min/ml. This difference was statistically 
significant p=0.047. 
The prognostic utility of admission PLA2 in predicting severe AKI requiring dialysis was 
analysed using the ROC curve (Figure 20). The area under the curve is was 0.752. An 
admission PLA2 level > 89.84 μmol/min/ml predicted requirement of haemodialysis with 
a sensitivity of 63.6% and a specificity of 83.8%. 
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Figure 21 demonstrating the median PLA2 activity with IQR in patients with Russell’s 
viper bite with AKI who required dialysis and who did not require dialysis. It is noted 
that the admission PLA2 values were significantly higher for patients who required 
haemodialysis. 
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ROC CURVE OF PLA2 ACTIVITY TO PREDICT AKI REQUIRING 
HAEMODIALYSIS 
 
Figure 20 showing the ROC curve for the admission PLA2 values to predict the severity 
of AKI assessed as per the requirement of haemodialysis. The area under the curve is 
0.752. PLA2 values above 89.84 μmol/min/ml predicts requirement of haemodialysis 
with a sensitivity of 63.6% and a specificity of 83.8%. 
 
3. PLA2 level in pure neurotoxicity requiring mechanical ventilation and no mechanical 
ventilation (Figure 22) 
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The severity of neuroparalysis was assessed by the need for mechanical ventilation. The 
patients who required mechanical ventilation for respiratory muscle weakness had a 
median admission PLA2 activity of 63.48 (IQR 54.9-72.8) μmol/min/ml. The patients 
with neurotoxicity who did not require mechanical ventilation had a median admission 
PLA2 activity of 58.54(IQR 52.4-71.2) μmol/min/ml. This difference was not statistically 
significant (p=0.515). 
 
Figure 23 showing the box plot of PLA2 values in patients who required mechanical 
ventilation and those who did not require mechanical ventilation. 
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PLA2 activity and mortality 
There was only one death among the patients in whom PLA2 was estimated. Hence 
meaningful conclusions could not be drawn between the co-relation of PLA2 activity 
with mortality.  
Temporal profile of PLA2 activity in patients with systemic envenomation 
There was significant declining trend in the mean PLA2 values from the time of 
admission till day 4 (p value=0.008). It is not clear whether the decline in PLA2 activity 
is due to decrease in venom PLA2 or endogenous PLA2.  
 
Figure 24 showing the decline in PLA2 values (represented diagrammatically as 
mean±2SD over time). 
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Discussion  
The patients included in this study were referred from main government hospitals. Hence 
these patients were most severely envenomated patients of Vellore and adjacent districts. 
We have summarised discussion under 2 sections. 1. Clinical profile of snake 
envenomation. 2. PLA2 assay- diagnostic and prognostic utility 
Clinical profile of snake envenomation 
1. Geographical variation in envenomation syndrome-Predominance of Russell’s’ 
viper envenomation and low rate of elapidae bite 
The most common clinical syndrome associated with systemic envenomation in our 
setting was haemotoxicity (Viperine envenomation). In haemotoxic patients, venom 
induced consumptive coagulopathy was the most common manifestation. The prevalence 
of a combination of local swelling, haemotoxicity with neurotoxicity and/or renal failure 
accounted for nearly two thirds of the patients with systemic envenomation. This 
suggests that Russell’s viper envenomation is the most common cause of systemic 
envenomation in Tamil Nadu. This contrasts to studies from Western and Eastern India 
which show neurotoxicity as the most common envenomation syndrome. In this study the 
rate of Elapidae bites contributed to less than one fifth of the total systemic envenomation 
in Tamil Nadu. These results suggest that there is geographical variation in envenomation 
syndromes in Tamil Nadu compared to other parts of India. 
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2. Neuroparalysis spectrum in envenomation syndromes 
 The serious manifestations of neurotoxicity like bulbar weakness and limb weakness 
were  short (1 day), but ptosis and ophthalmoplegia persisted for longer duration (3-5 
days). The pattern of neuroparalysis did not show any species difference with regard to 
the incidence of ptosis, opththalmoplegia or bulbar weakness but the frequency of 
respiratory muscle weakness and limb weakness were higher in the Elapidae bites when 
compared to Russell’s viper envenomation. The occurrence of neurotoxicity in Russell’s 
viper envenomation was very high (85.3%, n=87). But the severity of neurotoxicity in 
Russell’s viper envenomation was less when compared to Elapidae bites. Ptosis was the 
most common manifestation followed by ophthalmoplegia. The duration of various 
manifestations of neurotoxicity were short lived with lesser days for reversal with ASV in 
Cobra envenomation where as the duration of neurotoxicity in Krait/Russell’s viper 
envenomation persisted for longer. 
 We report a higher incidence of neurotoxicity in Russell’s viper envenomation (85.3%) 
when compared to Sri Lanka (59%). The neuroparalysis spectrum of Russell’s viper in 
Tamil Nadu is similar to that of Sri Lanka with ptosis and ophthalmoplegia being the 
most common manifestation. The incidence of severe neurotoxic manifestations like 
respiratory muscle weakness and bulbar weakness in Russell’s viper envenomation were 
relatively rare which is consistent with the results from Sri Lankan study. 
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3. High rate of AKI and need for dialysis with Russell’s viper bites 
The incidence of AKI in Russell’s viper envenomation was 56.9% (n=58). One in three 
patients with Russell’s viper envenomation required Haemodialysis 33.3% (n=34). This 
was much higher when compared to the incidence of AKI in Russell’s viper bite in Sri 
Lankan study (19%). 
The high rate in the present study could be due to referral bias as many patients may have 
been referred because of the presence of AKI. 
4. Significant myotoxicity with Russell’s viper bites 
The incidence of muscle injury in Russell’s viper bite was very high (45.05%).  Among 
the patients with Russell’s viper bite with AKI, nearly half (48.39%) had features of 
rhabdomyolysis. This is much higher when compared to the Sri Lankan study where the 
incidence of muscle injury was documented as 24% with Russell’s viper envenomation. 
These results suggest that muscle injury could be an important pathogenetic factor in 
development of AKI in Russell’s viper envenomation. 
5. Cardiotoxicity with Russell’s viper bites 
We report high rates of myocarditis associated with Russell’s viper envenomation. 7.84% 
n=8 of the patients with Russell’s viper envenomation had clinical/laboratory features of 
myocarditis and ECHO proven LV dysfunction. The cardiac effects of Russell’s viper in 
Sri Lanka were documented as 3-12% . The literature of snake bite emphasised the 
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importance of Cobra bite induced myocarditis. However in this study nearly all the cases 
of myocarditis were due to Russell’s viper bite. 
6. Abdominal pain in Russell’s viper bite 
The incidence of abdominal pain in Russell’s viper bite was estimated to be 15.53% 
which was much lower than the Sri Lankan data.   In patients with Russell’s viper 
envenomation with abdominal pain at presentation, 84.2% n=16 developed VICC, 78.9% 
N=15 developed neurotoxicity and 63.2% N=12 developed AKI which was similar to that 
of the Sri Lankan data. The literature in India has emphasised the association of 
abdominal pain with common Krait bite. However in this study abdominal pain was 
commonly associated with Russell’s viper bite. 
 
7. Pituitary insufficiency/Cerebrovascular accident with Russell’s viper 
There were 2 cases of acute pituitary insufficiency documented with Russell’s viper 
envenomation (1.96% ). It is a rare manifestation of Russell’s viper envenomation similar 
to the data from Sri Lanka. Prospective studies from Myanmar show a higher rate of 
pituitary insufficiency.(68)  Pituitary insufficiency may have been under diagnosed in this 
study as pituitary hypofunction may have been subclinical and required followup 
hormonal testing. 
The incidence of non hemorrhagic cerebrovascular accident was 1.96% (n=2) among 
Russell’s viper bite which was similar to the clinical data from Sri lanka(1.8%). 
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8. Mortality associated with Russell’s viper envenomation 
The mortality was exclusively associated with Russell’s viper envenomation. 4.90% 
(n=5) of the patients with Russell’s viper envenomation succumbed. The mortality was 
due to a combination of venom induced consumptive coagulopathy, AKI, 
rhabdomyolysis, local cellulitis in all patients and septic shock in the majority. The 
mortality due to Russell’s viper envenomation is higher than Sri Lanka (2.6%). 
9. Possible syndrome variation of Russell’s viper bite in Tamil Nadu 
When compared to data from Sri Lanka, the patients in this study had higher rate of 
neurotoxicity, AKI and muscle injury, greater requirement of blood transfusion and 
dialysis and greater mortality. This could suggest that the Russell’s viper bite in Tamil 
Nadu causes greater organ damage and morbidity. These may represent variations in 
venom composition between Russell’s viper in Tamil Nadu and Sri Lanka. 
10. Clinical Antivenom inefficacy in Russell’s viper envenomation  
In this study the antivenom dose requirement was highest with Russell’s viper 
envenomation syndrome. The ASV requirement in Viperine envenomation (most of 
which were Russells viper envenomation) was significantly higher than Elapidae bites. 
The greater antivenom requirement and the high rates of complications (product support 
requirement and haemodialysis) in Russell’s viper bite probably indicate a relative 
inefficacy of polyvalent ASV to neutralize Russell’s viper envenomation. The potential 
explanations for this inefficacy include: (1) lack of neutralisation of toxic venom proteins 
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by antivenom and (2) occurrence of organ injury in muscle and kidney prior to the 
initiation of antivenom.  The inefficacy of ASV for Russell’s viper envenomation has not 
been reported so far in the literature. 
11. Allergy anaphylaxis rates 
ASV reaction occurred in more than one third of the patients who were administered 
ASV. The common manifestations were mild like itching and urticaria which did not 
interfere much with the ASV protocol (same dose was administered over a longer time). 
The serious complications like bronchospasm and anaphylaxis were associated with 
poorer outcome and reduced use of ASV. This was similar to the incidence of ASV 
reactions in other geographical regions of South East Asian countries. (69) 
Evaluation of Phospholipase A2 assay in diagnosis and assessment of severity of 
snake envenomation 
The aims of this study were to assess the utility of serum PLA2 in (1) Diagnosis of snake 
envenomation (2) Assessment of severity of snake envenomation. 
The main findings of this study were: 
1. PLA2 levels were elevated in snake bite envenomation in comparison to normal controls 
2. PLA2 levels were elevated in both envenomated and non envenomated snake bite and 
there was no significant difference.  
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3. PLA2 was elevated in viper bite syndromes compared to elapidae syndromes. PLA2 
levels showed greater elevation in more severe viper bite syndromes requiring blood 
transfusion and dialysis.   
4. PLA2 levels declined with time 
Can serum PLA2 be used a test to diagnose snake envenomation? 
The results suggest that while easy this assay is easy to perform it does not distinguish 
between envenomation and no envenomation in snake bite. Therefore this study shows 
that serum PLA2 cannot be used as a diagnostic test for snake envenomation. The 
elevation of serum PLA2 in viper bites compared to Elapidae bites suggest that it could 
be used to distinguish between haemotoxic and pure neurotoxic syndromes. A PLA2 
level > 79.33 μmol/min/ml can distinguish Viperidae envenomation from Elapidae with a 
sensitivity of 50 % and specificity of 87.3%. However the clinical syndromes of Viper 
bite and Elapidae bites are clearly distinguishable and hence there may not be a role of a 
lab test to make this differentiation. 
Can serum PLA2 be used to assess severity of envenomation? 
PLA2 is elevated in more severe viper envenomation requiring transfusion and dialysis. 
The diagnostic test evaluations showed that PLA2 levels in viper bite predicted need for 
blood transfusion and dialysis with reasonable sensitivity and specificity. A PLA2 
activity > 88.02 μmol/min/ml predicted requirement of product support with a sensitivity 
of 63% and a specificity of 84%. An admission PLA2 level > 89.84 μmol/min/ml 
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predicted requirement of haemodialysis in AKI with a sensitivity of 63.6% and a 
specificity of 83.8%. 
However it is not clear if the elevation detected is endogenous due to inflammation and 
organ dysfunction or from the venom. Since the severity of renal injury and 
haemotoxicity in viper bite can be easily diagnosed through standard coagulation and 
renal tests, the role of PLA2 as a prognostic marker is limited.  
Overall the study shows that PLA2 levels cannot be used to diagnose systemic 
envenomation though it may have some role in distinguishing between Viper and 
Elapidae bites and in predicting prognosis in Viper bites. The study highlights the 
limitation of using enzymes assays to diagnose snake envenomation. Although PLA2 is 
an enzyme which was described to be present in Viperine and Elapidae species of snakes 
in India, its role as a diagnostic and prognostic test may be limited in our setting. Further 
work is required to develop a diagnostic test for snake envenomation both to identify 
diagnose systemic envenomation and identify the species of snake.   
Further research work 
Russells’s viper envenomation 
Russell’s viper envenomation is the important envenomation syndrome in Tamil Nadu. 
Detailed work is required to improve treatment for Russell’s viper envenomation 
including: 
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(a) clinical spectrum and geographical syndrome variations in Russell’s viper 
envenomation.  
(b) Characterisation of venom proteins causing toxicity of Russell’s viper envenomation 
in Tamil Nadu 
(c) Further work on documenting efficacy of ASV for Russell’s viper envenomation and 
improving quality of antivenom.  
Diagnostic tests for snake bite 
The present study showed the limitation of using enzymatic tests for diagnosis of snake 
envenomation. Therefore further work is required develop specific immunoassays for 
snake bite such has been developed in Australia. This involves identifying specific 
venom proteins of individual snakes (the big 4) and development of antibodies against 
these proteins that do not cross react with human antibodies.   
 
Limitations of the study 
1. The case distribution in the community may be different since most of the cases 
which were studied were referral cases with significant complications.   
2. PLA2 measurements could be influence by delay in transfer, prior antivenom 
administration 
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Conclusion 
1. Clinical study 
Russell’s viper envenomation is the most common cause of systemic envenomation in 
Tamil Nadu which is associated with high rates of neurotoxicity, muscle injury and AKI, 
need for blood transfusion and dialysis and significant mortality. This severe clinical 
envenomation syndrome could represent a syndrome variation of Russell’s viper in Tamil 
Nadu in comparison to Sri Lanka. The higher dose of ASV and significant complication 
rate suggests that there is a relative inefficacy of ASV to neutralize the envenomation of 
Russell’s viper when compared to other snake species. The study also documented the 
differences in the neuroparalysis spectrum of Russell’s viper envenomation with lower 
rate of limb and respiratory muscle paralysis when compared to Cobra and Krait 
envenomation. 
2. PLA2 as a diagnostic test for snake envenomation 
PLA2 activity is not a useful test to diagnose snake bite patients with systemic 
envenomation although it may have a role in distinguishing between Viper and Elapidae 
bites and assessing prognosis of Viper bites. 
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OP Number:                                       IP Number:                                           Date Enrolled:                                                                                                                                                                      
I. Patient Profile: 
Patient identification:         
Name:                         Age:                               Sex: M         / F    
Village:                                                                        District:                                             State: 
Date of Bite:     Date of admission: 
Time of bite:     Time of admission:    
Site of bite: RUL       RLL       LUL       LLL       Face       Trunk       Other        Bite site Unknown  
Local swelling: Y         / N                         Blisters: Y         / N                         Local Bleeding: Y        / N  
Place where bitten: Indoor          Outdoor            Unknown             
Activity of the person during the bite: Awake            Asleep          Unknown 
II. Identification of the snake:                            
Was the snake brought? : Y         / N                               
III First Aid Profile: 
 Tourniquet:  Y         / N                 Bite site Washed: Y         / N 
Previous Hospital Treatment: Y         / N 
If yes, proceed below: 
 Type of the hospital: PHC         CHC          District Govt.  hospital          Private hospital 
 Tourniquet: Y        / N          Time of removal of Tourniquet/Compression Bandage: 
 ASV administered outside: Y          /  N           If yes, number of vials:    
 History of allergy to ASV: Itching       Urticaria        Angiooedema (Swelling of Mouth & tongue)       
Bronchospasm         Anaphylaxis (Shock) 
IV. Study sample:  
 Bite Site Swab Obtained: Y         / N            
 Blood Sample Obtained: Y        / N            
 Urine Sample:  Obtained: Y         / N           
 Before ASV: Y        / N            
 Follow up blood sample at 12Hrs obtained: Y         / N            
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V. Clinical Profile at admission: 
Clinical Examination at Admission: 
BP < 90/60: Y        /  N            
Respiratory rate > 24/Min: Y        /  N            
Altered Sensorium: Y        /  N 
 If yes GCS:  
 
Bleeding Manifestations: 
Oral Mucosal Bleeding: Y        / N            
Hemoptysis: Y       /  N            
Hemetemesis: Y        /  N            
Melaena: Y       / N             
Hematuria: Y       /  N            
Bleeding from other sites: Y       /  N            
Neurological Manifestations: 
Higher mental functions-Handedness----- 
Intelligence---,consciousness-----, Memory-----, 
Orientation------, Emotion------Speech--------- 
Cranial nerves 
Visual acuity- 
Papilledema 
Colour vision 
Confrontation test 
Drooping of Eye Lids: Y       /  N            
Ophthalmoplegia: Y       / N          
Extraocular movements-   
Bulbar weakness- 
Neck Muscle weakness: Y       /  N            
Muscle weakness of limbs: Y       /  N          
If weakness is present   
Grade of Power  
RUL                                    LUL---------- 
RLL:                                    LLL--------- 
Single breath count- 
Renal Failure:  
Oliguria < 500ml/Hr: Y      /  N            
 
Abdominal findings 
Abdominal pain: Y       / N                   
Tone of the limbs- 
Deep tendon reflexes- 
Sensory Nervous system-Touch— 
Pain--- 
Temeprature----- 
Vibration---- 
Position sense------ 
Superficial reflexes- 
Babinski s sign- 
Rombergs sign- 
Cerebellar signs- 
Meningeal signs 
Skull/spine- 
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VI. Laboratory Profile at admission: 
 
 
 
 
 
 
Outcomes: (For patients with no clinical signs of envenomation for 24 hours) 
 Brought Dead         Discharged          DAMA           Referred to higher centre 
 Date of Discharge         Death             DAMA          Referral          :  
 Time of Discharge          Time of Death         : 
 If referred, reason for the referral : 
1. On Patient Request  
2. Need for Mechanical Ventilation 
3. Need for Dialysis 
4. Clinical Bleeding 
5. Others 
 
 
 
 
 
 
Platelets:  (1000-5, 00,000) 
 
 
 
Urine microscopy:  
Albumin 
Present        Absent 
 
Hematuria( More than 5 RBC) 
 
Present          Absent 
 
 
2  min WBCT: 
 Clotted within 20 min 
 
Incoagulable at 20 min 
Blood urea: 
 
                                  
 
 Serum Creatinine: 
 
                  
 
Clotting Time: 
Prothrombin Time (PT) Partial Thromboplastin (aPTT) 
Patient (sec) Control (sec) Patient (sec) Control (sec) 
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Daily Monitoring Proforma: 
 Day 1 Day 2 Day 3 Day 4 Day 5 
Bleeding Y      / N Y       / N Y      / N Y        / N Y        N 
Paralysis Y      / N Y       / N Y      / N Y       / N Y        N 
Local swelling Y      / N Y      / N Y      / N Y      / N Y        N 
Cardiotoxicity-BP 
Abnormal CVS 
Examination 
ECHO(if done) 
     
Platelets      
Serum Creatinine      
Urea      
PT/APTT      
Coagulopathy 
Fibrinogen 
Y      / N Y      / N Y      / N Y      / N Y      / N 
Ptosis  Y      / N Y      / N Y      / N Y      / N Y      / N 
Ophthalmoplegia Y      / N Y      / N Y      / N Y      / N Y      / N 
Single breath count      
Grade of power 
RUL/LUL/RLL/LLL 
     
Rhabdomyolysis 
LDH/CPK 
Y      / N Y      / N Y      / N Y      / N Y      / N 
Rare complications 
like CVA, 
blindness,ARDS, any 
other syndromes not 
described above 
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Treatment Data: 
Antivenom: Y      / N       If yes, proceed to the following:                   
Lyophilized        Liquid         Manufacturer name:                                                  Batch: 
Indication for ASV: Local Swelling      Coagulopathy      Shock       Neurological Symptoms Unclear 
ASV schedule: 
 
Allergic reactions to ASV:  Y        / N         If yes proceed to the following:                     
Itching       Urticaria     Angiooedema (Swelling of mouth & tongue)       Bronchospasm      Anaphylaxis (Shock)  
Treatment of Allergic reactions: Antihistamine       Hydrocortisone      Adrenaline        SC      IM      IV 
Preventive treatment for allergic reactions: Antihistamine      Hydrocortisone      Adrenaline        SC      IM       IV 
 
 
 
Blood transfusion: Y       / N 
If yes: Whole Blood      FFP      Platelets                 Number of transfusions:  
 
Mechanical ventilation: Y       / N Duration: (Days) 
Tracheostomy done    Y      / N 
Ventilator associated pneumonia Y      / N 
 
Neostigmine: Y      / N 
 
Dose 
 
Date 
 
Time 
 
Number of vials 
1st Dose    
2
nd
 Dose    
3rd Dose    
4th Dose    
5th Dose    
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Dialysis: Y       / N 
If yes:  Haemodialysis      Peritoneal dialysis                 Number of sessions of dialysis: 
 
Antibiotics given: Y         / N 
 
Antibiotics:  
 
Surgical intervention: Y        / N 
If yes: Debridement       Fasciotomy      Amputation       Others 
 
Need for Surgery: 
 
 
 
 
Final Case Summary: 
Recovered        Died      DAMA         Referred to higher centre 
Date of Discharge       Death      DAMA       Referral      :  
If referred, reason for the referral:  
 
If patient died, fill Proforma 4 (Death proforma) 
 
Subgroups: 0 
Number to be filled at the time of discharge: 
1. No envenomation 
2. Local swelling  only 
3. Haemotoxicity with local swelling  
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4. Haemotoxicity without local swelling  
5. Neurotoxicity only  
6. Neurotoxicity with Local swelling 
7. Haemotoxicity + Neurotoxicity  with  local swelling 
8. Haemotoxicity + Neurotoxicity  without local swelling 
9. Haemotoxicity + Neurotoxicity + Renal failure with local swelling 
10. Haemotoxicity + Neurotoxicity + Renal failure without local swelling 
11. Haemotoxicity + Renal failure with local swelling 
12. Haemotoxicity + Renal failure without local swelling 
13. Others              Explain: 
 
Consultant/Doctor:  
Name and designation: 
 
Signature:                                                                    Date: 
 
Death Proforma: 
 
Date of Death: 
 
Time of death: __________________________ 
  
Cause of death (tick appropriate): 
1. Due to snake bite complications 
a. Respiratory failure 
b. Bleeding            Indicate site of bleeding: 
c. Renal failure 
d. Cellulitis 
e. Cardiac Arrhythmias          Cardiac Failure 
f. ARDS  
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2. Anaphylactic shock  
3. Treatment associated death 
a. Ventilator associated pneumonia 
b. Dialysis associated problems 
c. Tube dislocation 
d. Ventilator Malfunction 
e. Other nosocomial infections 
f. Others (Unspecified) 
4. Any other factors contributing to death (unrelated to snakebite or treatment)  
 
 
 
 
Place of Death (tick appropriate): 
Emergency ward 
Ward 
 ICU 
 During transfer  
 After referral 
 
Postmortem performed: Y          / N 
 
Postmortem findings:  
a) 
b) 
c) 
d) 
 
Study coordinator is to inform CMC on date of death. Death proforma and copy of death 
certificate to be send within 1 week. 
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Data Sheet 
 
Study.NoAge Sex Site of bite Date of Bite Prior ASVAllergy to ASVItching UrticariaAngiooedemaBronchospasmAn phylaxisTotal ASVTime GapSnake brought Snake SpeciesNeurotoxicityPtosis OpthalmoplegiaBulbar weaknessRespiratory muscle weakness
1 25 M LUL 2/13/2014 0 0 0 0 0 0 0 0 8 Y Russels kukri 0 0 0
2 54 M LUL 2/16/2014 0 0 0 0 0 0 0 0 1 N 0 0 0
3 35 M LUL 2/24/2014 2 1 1 1 0 0 0 2 n Y Saw scaled Viper1 1 0
4 39 F LUL 3/5/2014 0 0 0 0 0 0 0 20 2 N 0 0 0
5 38 M RLL 3/5/2014 0 0 0 0 0 0 0 12 4 N 0 0 0
6 50 M RLL 3/17/2014 10 0 0 0 0 0 0 10 n N 0 0 0
7 53 M RLL 1/22/2014 0 0 0 0 0 0 0 10 6 N 1 1 1
8 26 M LLL 3/20/2014 0 0 0 0 0 0 0 6 9 N 1 1 0
9 35 M RLL 2/15/2014 18 0 0 0 0 0 0 18 23 N 1 1 0
10 32 M LLL 3/24/2014 0 0 0 0 0 0 0 14 2 N 1 1 1
11 26 F LLL 4/6/2014 2 0 0 0 0 0 0 14 3 N 0 0 0
13 29 M LLL 4/10/2014 17 0 0 0 0 0 0 17 64 N 1 1 1
14 35 M RLL 4/15/2014 0 0 0 0 0 0 0 6 78 N 0 0 0
15 45 M LLL 4/15/2014 18 0 0 0 0 0 0 28 32 N 1 1 0
16 39 M LUL 4/19/2014 0 1 1 1 0 0 0 6 6 N 1 1 1
17 52 M LLL 4/20/2014 0 0 0 0 0 0 0 10 10 N 1 1 0
20 55 M LLL 4/28/2014 2 1 1 0 0 0 0 10 7 N 1 1 1
21 35 F RLL 5/5/2014 1 1 1 1 0 0 0 11 2 N 1 1 1
22 25 F RLL 5/9/2014 10 1 1 1 0 0 0 18 20 N 1 1 0
23 59 F RLL 5/10/2014 0 0 0 0 0 0 0 10 n N 1 1 0
24 47 M RLL 5/16/2014 24 1 1 1 0 0 0 34 44 N 1 1 0
25 65 F LUL 4/27/2014 0 1 1 0 0 0 0 10 36 N 1 1 1
26 50 M RLL 5/23/2014 2 1 1 0 0 0 0 10 7 N 0 0 0
28 16 F RUL 5/24/2014 16 1 1 0 0 0 0 32 29 N 1 1 0
29 21 M O 5/24/2014 20 0 0 0 0 0 0 44 36 N 0 0 0
30 25 F RLL 5/27/2014 10 0 0 0 0 0 0 37 2 N 1 1 1
31 40 F T 6/1/2014 5 0 0 0 0 0 0 5 1 N 1 1 0
32 45 M RLL 6/4/2014 10 1 1 0 0 0 0 20 4 N 1 1 1
33 25 M LLL 6/8/2014 2 0 0 0 0 0 0 20 n N 1 1 0
34 35 M LLL 6/10/2014 8 0 0 0 0 0 0 17 3 N 1 1 0
35 30 M LLL 6/17/2014 8 1 1 0 0 0 0 10 3 N 1 0 0
36 43 M LLL 6/19/2014 0 0 0 0 0 0 0 20 1 N 1 1 0
37 26 M T 6/21/2014 9 0 0 0 0 0 0 17 38 N 1 1 0
38 62 M RLL 6/27/2014 8 0 0 0 0 0 0 24 12 N 1 1 1
39 24 M LUL 7/5/2014 N 0 0 0 0 0 0 N 7 Y Cobra 0 0 0
40 23 M LLL 7/5/2014 10 0 0 0 0 0 0 18 5 N 1 1 1
41 28 F RLL 7/12/2014 N 0 0 0 0 0 0 16 6 Y Russels Viper 1 1 1
42 25 F LUL 7/13/2014 10 0 0 0 0 0 0 17 7 N 0 0 0
43 23 F LLL 7/13/2014 N 0 0 0 0 0 0 10 58 N 0 0 0
44 44 M LLL 7/19/2014 0 1 1 1 0 0 0 14 2 N 0 0 0
45 45 F RUL 7/16/2014 6 1 1 1 1 1 1 13 6 N 0 0 0
46 58 F RUL 7/7/2014 0 0 0 0 0 0 0 0 1 Y Indian Wolf snake0 0 0
47 21 F LUL 7/15/2014 13 1 1 0 0 0 1 15 32 N 0 0 0
48 24 M U 7/19/2014 0 0 0 0 0 0 0 10 N N 1 1 1
49 21 M LLL 8/4/2014 6 0 0 0 0 0 0 16 26 N 1 1 1
50 68 M LLL 8/4/2014 3 1 1 1 0 0 0 13 17 N 0 0 0
51 68 F RLL 8/1/2014 0 1 1 1 0 0 0 10 6 N 1 1 1
52 19 F RUL 8/8/2014 4 0 0 0 0 0 0 15 4 N 1 1 1
53 33 M RLL 7/26/2014 30 0 0 0 0 0 0 30 127 N 1 1 1
54 50 M RLL 8/3/2014 3 1 1 0 0 0 0 9 185 N 0 0 0
55 48 M RLL 8/11/2014 5 1 1 0 0 0 0 14 2 N 0 0 0
56 19 M LLL 8/17/2014 0 1 0 1 0 0 0 20 2 N 0 0 0
57 45 M RLL 8/21/2014 5 1 1 1 0 0 0 17 6 N 1 1 1
58 28 M RLL 8/22/2014 6 1 1 1 0 0 0 26 12 N 1 1 1
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Limb weaknessDuration of ptosisDurati n of ophthalmoplegiaDuration of bulbar weaknessDuration of limb weaknessHaemotoxicityWBCT Pt ValueAptt ValuePt -1/2 pt Aptt - 1/2 ptCPK LDH SymptomaticSeverityDuration of HaemotoxicityThrombocy peniaDIC Products supportAbdominal PainRenal failureNo of Dialysis
0 0 0 <10 min 10.4 29.2 0.94 0 115 0 0 0 0 0 0 0 0 0
0 0 0 <10 min 10.6 28.5 0.96 0 100 0 0 0 0 0 0 0 0 0
1 0 0 <20 m 13.5 26.5 11.9 0 0 0 0 0 0 0 0 0 0 0
0 0 1 > 20 m > 3 mins> 3 mins 18.6 92.5 434 762.8 1 1 1 1 1 0 1 1
0 0 1 <10 min 13.4 24.7 11.9 0 421 5081 1 1 1 1 1 0 1 3
0 0 1 > 20 m 47.2 17 14 0 2169 0 1 1 0 1 1 0 1 3
1 1 1 <10 min 1.7 33.3 12.5 0 960 0 1 1 1 1 0 0 1 0
1 0 1 <10 min 12.7 27.5 11.5 0 2128 0 1 1 1 1 0 0 1 4
1 0 1 > 20 m 15.1 28 11.9 0 6449 875 1 1 0 0 0 0 1 0
1 1 1 > 20 m > 2 mins> 3 mins 15.5 20.3 396 0 1 1 1 1 1 0 1 0
0 0 1 < 20 m 12.5 27 0 146 0 1 1 0 0 0 0 0 0
5 5 1 < 20 m 13.5 40.7 30 0 1436 546 1 1 1 1 0 0 0 0
0 0 1 < 20 m 15.6 36.4 11.8 0 7761 1394 1 1 1 0 1 0 1 5
4 0 1 > 20 m 13.8 31.3 11.5 0 853 1370 1 1 1 0 0 0 1 4
4 4 1 < 20 m 11.5 32 0 0 960 0 1 1 0 0 0 0 0 0
3 0 1 < 20 m 67.8 35.2 14.5 0 317 0 0 0 1 0 0 0 0 0
4 4 1 < 20 m 13 68 12.2 0 257 0 1 1 0 0 0 0 0 0
1 1 1 > 20 m 61.4 26.2 13.4 0 1520 1614 1 1 1 1 1 0 0 0
1 0 1 > 20m 15.2 31.1 11 0 2662 961 1 1 0 0 0 0 1 0
1 0 1 < 20 m 30.1 30.7 0 0 342 0 1 1 0 1 1 0 1 0
3 0 1 > 20 m 18.9 37 12.2 0 6611 2619 1 1 1 1 1 1 1 1
4 4 1 < 20 m 11.9 25 10.8 0 0 0 0 0 0 0 0 0 0 0
0 0 0 < 20 m 13.5 25.4 11.5 0 2189 0 0 0 0 0 0 0 0 0
1 0 0 < 10 m 13.7 28.4 11.5 0 0 0 0 0 0 0 0 0 0 0
0 0 1 > 20 m 27.3 41.1 12.2 30.3 7654 2166 1 1 1 1 1 1 1 1
5 5 1 < 10 m 28 28.7 13.7 0 27121 0 1 1 1 1 1 1 0 0
1 0 0 < 10 m 10.9 25.7 0.99 0 194 0 0 0 0 0 0 0 0 0
5 5 1 >20 m 32.4 40.9 13.9 27 1225 4799 1 1 0 0 0 0 1 0
1 0 1 > 20 m > 2 mins> 3 mins 14.3 36.4 2118 0 1 1 1 1 0 0 1 0
3 0 1 < 10 m 19.8 111.4 11.8 44.2 11380 0 1 1 1 1 0 0 1 0
0 0 1 > 20 m > 2 mins> 3 mins 88.2 0 936 0 1 1 0 1 0 0 0 0
3 0 1 > 20 m 29.3 92 14 71.6 138 0 1 1 1 1 1 1 0 0
3 0 0 < 20m 13.1 25 11.3 0 129 0 0 0 0 0 0 1 0 0
1 1 1 < 12 m 51 38.3 13.4 25 805 0 1 1 1 1 0 1 0 0
0 0 0 < 10 m 12.5 30.7 0 0 315 0 0 0 0 0 0 1 0 0
5 5 1 < 10 m 62 26 0 0 920 0 1 1 1 1 0 0 0 0
4 4 1 < 20 m 24.5 26 13.2 0 566 0 0 0 0 0 0 0 0 0
0 0 1 < 20 m 21.4 25.4 11.4 0 455 0 0 0 1 0 0 0 0 0
0 0 1 > 20 m 16.1 36.2 11.6 0 286 0 0 0 1 0 0 1 0 0
0 0 1 < 20 m 31 32.1 12 0 3368 0 1 1 1 1 1 0 0 0
0 0 1 < 20 m 25.7 29.2 12.1 0 0 0 0 0 1 1 0 1 0 0
0 0 0 < 20 m 10.1 25 0 0 0 0 0 0 0 0 0 0 0 0
0 0 1 > 20 m 19 37.7 11.9 27.9 951 0 1 1 1 1 0 0 0 0
3 3 0 < 20 m 11.4 26.2 0 0 319 0 0 0 0 0 0 1 0 0
3 3 1 > 20 m 11.9 24.8 0 0 4682 3520 1 1 1 1 0 0 0 0
0 0 1 > 20 m >2 mins > 3 mins 13.1 24 752 709 0 0 1 1 1 0 0 0
2 2 1 < 20 m > 2mins > 3 mins 12.4 18 226 5560 1 0 1 0 0 0 1 2
4 4 0 < 10 m 13.2 27.6 10.9 0 258 0 0 0 0 0 0 1 0 0
8 6 1 < 20 m 11.3 26.9 0 0 2041 2014 1 1 1 1 1 0 1 1
0 0 1 > 20 m 19.1 29 0 0 135 0 1 1 1 0 0 0 0 0
0 0 1 > 20 m > 2mins 110 33 0 0 0 1 0 0 1 0 0 0 0
0 0 1 < 20 m > 2mins 33.4 11.2 0 489 0 0 0 1 1 0 0 1 0
2 2 1 > 20 m > 2mins > 3 mins 11.8 31.4 0 0 1 0 0 1 0 0 0 0
10 10 1 > 20 m 33.8 56.8 12.4 31 9875 861 1 1 1 1 1 0 1 1
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HUS RhabdomyolysisLocal SwellingCe lulitisNecrotising FasciitisDuration of Mechanical VentilationOutcomeSyndromeComplicationsU usual syndromes LAB NO.Name NO OF ASV VIALS IN CMCPRE IOUS HOS ASVY DROMED1 AVG ODD2 AVG ODD3 AVG ODD4 AVG ODD5 AVG ODD6 AVG OD
0 0 1 0 0 0 1 2
0 0 0 0 0 0 1 1
0 0 1 0 0 0 1 2
0 0 1 1 0 2 1 9
1 1 1 1 0 3 1 11
0 1 1 1 0 0 1 8
0 1 1 1 0 0 1 7
0 1 1 1 0 3 1 9
0 1 1 1 0 0 1 7
0 1 1 1 0 6 1 9
0 0 1 1 1 0 1 7
0 1 1 0 0 3 1 9
0 1 1 0 0 5 1 9
0 1 1 1 0 0 1 9
0 0 0 0 0 5 1 6
0 0 1 1 0 0 1 7
0 0 1 1 0 0 1 7
0 1 1 1 1 2 1 7
0 1 1 1 0 0 1 9
0 1 1 1 0 0 1 9
0 1 1 1 0 4 0 9
0 0 1 1 0 4 1 7
0 1 1 1 0 0 1 3
0 0 1 1 0 0 1 6
1 1 1 1 0 10 0 11
0 1 1 1 0 1 1 7
0 0 1 1 0 0 1 6
0 1 1 1 0 0 1 9
0 1 1 1 0 0 1 9
0 1 0 0 0 2 1 9
0 1 1 1 0 0 1 7
0 0 1 1 0 0 1 7
0 0 0 0 0 5 1 5
0 1 1 1 0 0 1 7
0 0 1 1 0 0 1 13
0 1 1 1 0 3 1 7
0 1 1 1 0 0 1 7
0 0 1 1 0 0 1 3
0 0 1 1 0 0 1 3
0 1 1 1 0 0 1 3
0 0 1 1 0 0 1 3
0 0 0 0 0 0 1 1
0 1 1 1 0 0 1 13 myocarditis
0 0 0 0 0 3 1 5
0 0 1 1 0 0 1 7
0 1 1 1 0 2 1 7
0 1 1 1 0 2 0 9
0 0 1 1 0 0 1 6
1 1 1 1 0 9 2 13 HT,NT,RF,CVA,LOCAL SWELLING
0 0 1 1 0 0 1 3
0 0 1 1 0 0 1 3
0 1 1 1 0 0 1 11 myocarditis
0 0 1 1 0 0 1 7
0 1 1 1 1 11 0 7 Septic shock
111 
 
 
59 35 M LUL 8/26/2014 6 1 1 1 1 0 0 16 40 Y 1 1 0
60 40 M LLL 9/3/2014 5 1 1 1 0 0 0 15 15 N 0 0 0
61 38 M RLL 9/3/2014 2 1 1 1 0 0 0 12 5 N 1 1 0
62 44 M RLL 9/3/2014 0 0 0 0 0 0 0 10 n N 1 1 0
63 36 M LLL 9/7/2014 0 0 0 0 0 0 0 0 2 N 0 0 0
64 45 F RUL 9/6/2014 5 0 0 0 0 0 0 20 3 N 1 1 0
65 54 F LUL 9/13/2014 0 0 0 0 0 0 0 8 1 Y 0 0 0
66 28 F LLL 9/18/2014 2 0 0 0 0 0 0 20 4 Y Common Krait1 1 1 1 1
67 22 M RLL 9/18/2014 21 0 0 0 0 0 0 23 41 N 1 1 0 1 1
68 65 F RLL 9/20/2014 20 0 0 0 0 0 0 20 28 N 0 0 0 0 0
69 20 F LUL 9/24/2014 2 0 0 0 0 0 0 22 12 Y Russels Viper 1 1 0 0 0
70 24 M RUL 9/25/2014 8 0 0 0 0 0 0 8 6 Y Cobra 1 0 0 1 1
71 39 M LLL 9/27/2014 16 1 1 1 1 1 1 16 44 N 0 0 0 0 0
72 40 M LLL 9/27/2014 20 0 0 0 0 0 0 21 50 N 0 0 0 0 0
73 40 M RLL 9/29/2014 6 1 1 1 1 1 1 16 36 N 0 0 0 0 0
74 51 F LLL 10/8/2014 2 1 1 1 0 0 0 12 5 N 0 0 0 0 0
75 60 M RLL 10/13/2014 8 1 1 1 0 0 0 10 9 N 1 1 0 1 1
76 43 M RUL 10/15/2014 0 0 0 0 0 0 0 10 2 N 0 0 0 0 0
77 54 M RUL 10/16/2014 8 0 0 0 0 0 0 16 3 N 0 0 0 0 0
78 47 M RUL 10/16/2014 0 0 0 0 0 0 0 10 2 N 0 0 0 0 0
79 45 M LLL 10/18/2014 0 0 0 0 0 0 0 14 7 N 1 1 1 0 0
80 56 M SCROTUM 10/24/2014 0 0 0 0 0 0 0 10 12 N 1 1 1 1 1
81 47 F RLL 10/24/2014 3 1 1 1 0 0 1 13 5 N 1 1 1 0 0
82 60 F LUL 11/2/2014 4 1 1 0 0 0 0 18 8 N 0 0 0 0 0
83 25 M RLL 11/11/2014 8 0 0 0 0 0 0 20 2 N 1 1 1 0 0
84 24 F LLL 11/16/2014 6 0 0 0 0 0 0 16 15 N 1 1 1 0 0
85 30 M LLL 12/6/2014 18 0 0 0 0 0 0 18 4 N 1 1 0 0 0
86 55 M RLL 12/9/2014 20 0 0 0 0 0 0 20 6 N 1 1 1 1 1
87 60 F RUL 12/11/2014 20 0 0 0 0 0 0 30 1 N 1 1 1 1 1
88 35 F LLL 12/19/2014 5 1 1 1 0 1 0 15 2 N 1 1 1 0 1
89 54 M LLL+RLL 12/19/2014 10 0 0 0 0 0 0 24 2 N 1 1 1 0 1
90 25 M RLL 1/4/2015 10 1 1 0 0 1 0 22 7 N 1 1 1 0 0
91 35 F RLL 1/21/2015 2 1 1 1 1 0 0 12 6 N 1 1 1 0 0
92 62 M RUL 1/20/2015 10 0 0 0 0 0 0 14 5 N 0 0 0 0 0
93 48 M LLL 2/1/2015 8 0 0 0 0 0 0 18 4 N 1 1 1 1 1
94 37 M RLL 2/5/2015 0 1 1 1 1 1 1 10 3 N 0 0 0 0 0
95 19 M RUL 2/3/2015 10 1 1 1 0 0 0 20 4 N 0 0 0 0 0
96 51 M RLL 2/13/2015 0 1 1 1 0 0 0 10 4 N 1 1 1 0 0
97 50 F RLL 2/13/2015 4 1 1 1 1 0 1 14 5 N 0 0 0 0 0
98 24 M LLL 2/14/2015 10 0 0 0 0 0 0 20 3 N 1 1 1 1 1
99 16 F RLL 2/18/2015 10 0 0 0 0 0 0 20 2 N 1 1 1 0 0
100 60 M RUL 2/20/2015 NA 0 0 0 0 0 0 14 54 N 0 0 0 0 0
101 30 F LLL 2/27/2015 20 0 0 0 0 0 0 30 1 N 1 1 1 1 1
102 32 F RLL 3/3/2015 25 1 1 1 0 0 0 29 4 N 1 1 1 1 1
103 24 M LLL 3/13/2015 8 0 0 0 0 0 0 18 2 N 1 1 1 0 0
104 27 M LLL 3/15/2015 12 0 0 0 0 0 0 20 1 N 1 1 1 1 1
105 30 F RLL 2/21/2015 4 0 0 0 0 0 0 20 3 Y Russels Viper 0 0 0 0 0
106 31 M LLL 3/21/2015 NA 0 0 0 0 0 0 13 6 N 1 1 1 1 0
107 28 M LLL 4/5/2015 26 1 1 1 1 1 1 36 1 N 1 1 1 0 0
108 43 M LUL 4/7/2015 1 0 0 0 0 0 0 11 8 N 1 1 1 0 0
109 34 M FACE 4/7/2015 11 0 0 0 0 0 0 17 3 N 1 1 1 1 1
110 36 M LLL 4/8/2015 25 1 1 1 0 1 0 35 4 N 1 1 1 1 1
111 26 M RUL 4/17/2015 1 0 0 0 0 0 0 13 5 N 1 1 1 0 1
112 18 M RUL 4/20/2015 0 0 0 0 0 0 0 10 14 N 1 1 1 0 0
113 35 M LLL 4/22/2015 6 1 1 0 0 0 0 22 1 N 1 1 1 0 0
114 51 F Trunk-gluteal region4/24/2015 0 0 0 0 0 0 0 10 6 N 1 1 1 0 0
115 55 F RUL 4/26/2015 10 0 0 0 0 0 0 18 3 Y Common Krait (GVMC)1 1 1 0 0
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2 0 1 < 15 m 14.9 13.8 11.7 0 0 0 0 0 1 0 0 0 1 0
0 0 1 > 20 m > 2mins > 3mins 13.9 25 0 0 1 1 0 1 0 0 0 0
3 0 0 < 10 m 11.6 26 0 0 0 0 0 0 1 0 0 0 0 0
2 0 0 < 10 m 10.3 28.4 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0  < 10 m 10.3 25.7 0 0 83 432 0 0 0 0 0 0 0 0
3 0 1 > 20 m > 2 mins> 3 mins 12 25 5341 0 1 1 1 1 1 0 0 0
0 0 1  > 20 m 34.7 58.9 18 0 1713 7620 1 1 1 1 1 0 1 3
1 5 5 5 3 0 <10 min 12.6 34 77.9 0 96.2 0 0 0 0 0 0 0 0 0 0
0 4 0 6 0 1 > 20 m 22.4 43.7 12.4 29.7 0 >2000 1 1 10 1 1 1 0 1 4
0 0 0 0 0 1 < 15 m 16.6 37.5 13 33.7 3375 2767 1 0 4 1 1 1 0 1 4
0 1 0 0 0 1 > 20 m 30.3 34.8 11.8 0 396 0 0 0 1 0 1 0 0 0 0
0 0 0 2 0 0 < 5 m 12.8 23.1 10.8 0 322 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 < 10 m 17.2 31.7 11.5 0 460 614.9 0 0 4 1 1 0 0 0 0
0 0 0 0 0 1 > 20 m 12.4 24.4 1.12 0 148 618 1 1 5 1 1 0 0 1 0
0 0 0 0 0 1 > 20 m 23.2 29.6 12.3 0 2634 0 1 1 5 1 1 1 0 1 1
0 0 0 0 0 1 > 20 m clot clot clot clot 88 0 0 0 1 0 1 0 1 0 0
1 2 0 3 2 0  < 10 m 11.8 22.8 0 0 80 0 0 0 0 0 0 0 1 0 0
0 0 0 0 0 1 > 20 m > 2 min > 3 mins 12.5 25 296 0 1 1 1 0 1 0 1 0 0
0 0 0 0 0 1 > 20 m 18.7 35.5 11.2 0 0 0 1 0 1 1 1 0 0 0 0
0 0 0 0 0 1 > 20 m > 2 mins 43.4 13.6 25 720 0 0 0 2 1 1 0 0 0 0
0 3 3 0 0 1 > 20 m > 2 mins 31 13.4 0 0 0 0 0 1 1 1 0 0 0 0
0 2 3 2 0 0 < 10 m 10.1 1.2 0 0 0 0 0 0 0 0 0 0 0 0 0
0 2 2 0 0 0 < 15 m 14.1 27.2 11.5 0 299 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 1 < 20 m 16.6 24 11.5 0 0 0 1 1 1 0 1 1 0 0 0
0 2 2 0 0 1 > 20 m 15.7 243 12.3 0 0 0 0 0 1 0 1 0 0 0 0
0 2 2 0 0 1 < 20 m 17.7 25 0 0 4916 2398 1 1 1 0 0 0 0 0 0
0 2 0 0 0 1 < 10 m 15.5 27.5 11.6 0 9333 2239 1 1 1 1 1 0 0 1 0
1 4 5 2 2 1 > 20m 23.9 34.8 12.8 0 23200 5200 1 1 2 1 1 1 0 1 10
0 3 4 4 2 0 < 10 m 11.6 24.3 0 0 370 0 0 0 0 0 0 0 0 0 0
1 2 2 0 2 0 < 10 m 10 24 0 0 66 0 0 0 0 0 0 0 0 0 0
0 5 6 0 0 1 < 20 m 31.6 44.4 13.5 33 1908 1984 1 1 3 1 1 1 0 0 0
0 3 3 0 0 0 < 10 m 11.6 30.2 0 0 0 0 0 0 0 0 0 0 1 0 0
0 2 3 0 0 1 > 20 m 12.4 32.2 11.7 0 256 0 0 0 1 0 0 0 0 0 0
0 0 0 0 0 1 < 20 m 11.9 24.3 0 0 70 726 0 0 6 1 0 0 0 1 0
0 4 5 4 0 1 > 20 m 54.2 34.2 15.4 0 1261 2128 1 1 5 1 1 1 0 1 4
0 0 0 0 0 1 > 20 m 10.7 28.2 11.8 30.2 139 0 0 0 3 0 1 0 0 0 0
0 0 0 0 0 1 < 20 m 12.4 25.6 0 0 320 2783 1 1 1 1 1 0 1 1 5
0 4 5 0 0 1 < 20 m 14 36.8 11 0 61 0 0 0 2 0 0 0 0 1 0
0 0 0 0 0 1 > 20 m 22.7 64 12.4 33.2 120 504 1 1 5 1 1 1 0 1 4
1 3 4 2 2 1 > 20 m 23.8 52.3 11.9 35.7 42088 0 0 0 5 1 1 1 1 1 5
0 4 5 0 0 1 > 20 m 22.3 28.7 11.9 0 966 0 0 0 3 0 0 0 0 0 0
0 0 0 0 0 1 > 20 m clot clot clot clot 417 1025 1 1 3 1 1 1 0 1 0
1 2 2 2 2 1 > 20 m 20 27.4 12.1 0 1081 2741 1 1 3 1 1 1 0 1 3
0 5 5 2 0 1 > 20 m 13.5 31.1 10.7 0 3720 1155 1 1 5 1 1 1 0 1 1
0 3 3 0 0 1 < 10 m 15.4 24.2 11.9 0 415 0 1 1 1 0 0 0 1 0 0
0 4 5 1 0 1 > 20 m 18 30.4 12.4 0 3883 0 0 0 2 1 1 0 0 0 0
0 0 0 0 0 1 > 20 m> 2 mins> 3 mins 0 36 238 0 1 0 1 0 1 0 0 0 0
0 4 5 2 0 1 > 20 m 20.7 49.3 12.7 34.4 1523 2146 1 1 5 1 1 1 1 1 5
0 3 4 0 0 1 > 20 m 23 160.1 11.7 83.7 8032 0 1 1 4 1 1 1 1 1 3
0 3 4 0 0 1 > 20 m 22.3 25.6 13 0 0 505 1 1 2 1 1 0 0 0 0
0 5 5 3 2 1 < 20 m 14.1 51.3 11 39.6 1546 1011 0 0 5 1 1 0 1 1 0
1 4 5 4 3 1 > 20 m 15.6 27.9 11.4 0 3296 1502 1 1 5 1 1 1 0 1 4
0 4 5 0 0 0 < 20 m 11.7 35.7 0 0 3214 0 0 0 0 0 0 0 0 0 0
0 4 4 0 0 0 <  20 m 12.2 33 0 0 547 0 0 0 0 0 0 0 0 0
0 4 5 0 0 1 > 20 m 68 32 13 0 619 1609 1 1 1 0 1 0 1 4
0 3 3 0 0 1 > 20 m 35 31.1 12 0 219 0 1 1 1 1 1 0 0 0
0 3 4 0 0 0 < 20 m 10.8 31.5 0 0 300 310 0 0 0 0 0 0 1 0 0
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0 0 1 1 0 0 2 9
0 0 1 1 0 0 1 3
0 0 1 1 0 0 1 6
0 0 1 1 0 0 1 6
0 0 0 0 0 0 1 1
0 1 0 0 0 20 1 8
0 1 1 1 0 0 1 11
0 0 0 0 0 9 1 5
0 1 1 1 0 5 1 9 2 PASUPATHI 8 13 HT+RF+LS0.752 0.517 0.473 0.433 0.43
0 1 1 1 0 0 1 11 3 SUBATHABEEN 20 HT+LS 0.426 0.407 0.626 0.546 0.464
0 0 1 1 0 0 1 7 4 INDUMATHID1-10, D2-10N 0.294 0.318 0.255
0 0 1 1 0 0 1 6 5 KRISHNAMOORTHYN 8 LS 0.278 0.336 0.337
0 0 1 1 0 0 1 3 Shock 6 MURUGANN 8 HT+LS 0.473 0.385 0.391 0.307 0.575
0 1 1 1 0 0 1 11 7 MANI 6 20 0.283 0.281 0.255 0.239 0.287
0 1 1 1 0 21 1 11 8 MOHAN 10 6 HT+RF+LS0.528 0.532 0.482 0.458 0.406
0 0 1 1 0 0 1 3 9 CHANDRAD1-10, D2-2 2 HT+NT+ASV0.253 0.258 0.275
0 0 0 0 0 0 1 5 10 BALU 10 N NT 0.287 0.287 0.254 0.292
0 0 1 1 0 0 1 3 11 MOHAN J
0 0 1 1 0 0 1 3 12 KUMAR 2 8 HT+NT+LS0.568 0.526
0 0 1 1 0 0 1 3 13 RAVIKUMAR 0.388 0.226 0.246 0.292 0.281
0 0 1 1 0 0 1 7 14 CHINNAPAD1-8, D2-2N HT+NT+LS0.468 0.452 0.457 0.445 0.394
0 0 1 1 0 0 1 6 15 PARASIVAM 10 N NT 0.312 0.247 0.244 0.216 0.211
0 1 1 1 0 0 1 6 16 PUSHPA24.10.14 D1-10,D2-2 25.10.14 D3-6N NT+LS 0.672 0.545 0.5 0.318 0.429
0 0 1 1 1 0 1 3 17 KUPPAMAL 0.493 0.479 0.28 0.643 0.554
0 0 1 1 0 0 1 7 18 SRINIVASAN 0.602 0.428 0.429
0 1 1 1 0 0 1 7 19 SASIKALA 10 6 HT+NT+LS0.296 0.296 0.273 0.59 0.624
1 1 1 1 0 0 1 9 20 VENKATESHN 17 HT+NT+RF+LS0.253 0.29
1 1 1 1 1 9 1 9 21 MANI 6 20 0.611 0.622 0.468
0 0 1 1 0 2 1 6 22 PAVADAI 10 20 NT+LS 0.243 0.295 0.305
0 0 1 1 0 0 1 6 23 VARALAKSHMI 0.519 0.478 0.367 0.373
0 1 1 1 0 0 1 7 24 GOVINDARAJALU10 10 HT+NT+LS0.242 0.269 0.232 0.32 0.511
0 0 0 0 0 0 1 5 25 VIGNESHD1-6, D2-10 8 HT+NT+RF+LS0.279 0.302
0 0 1 1 0 0 1 7 26 SUJATHA 10 2 HT+NT+LS0.564 0.552 0.471 0.487
0 0 1 1 0 0 1 11 27 SUNDRAMOORTHY4 10 HT+LS 0.439 0.429 0.431 0.416 0.582
1 1 1 1 0 7 1 9 VAP ET BLEED,SECONDARY HTN DUE TO AKI28 ANJANAN 10 8 HT+NT+RF+LS0.706 0.523 0.535 0.501 0.475 0.445
0 0 1 1 0 0 1 3 ASV ANAPHYLACTIC SHOCK 29 SRINIVASAN 0.328 0.666 0.611 0.566
1 1 1 1 0 6 1 11 Enterococcal sepsis 30 MUNISAMY 0.484 0.484 0.601 0.481 0.36
0 1 1 1 0 0 1 9 31 SUBRAMANI 10 N NT+LS 0.848 0.828 0.81 0.756
1 1 1 1 0 0 1 11 Shock 32 SARASWATHI10 4 HT+RF+LS0.709 0.662 0.611 0.587 0.88
1 1 1 1 0 6 1 9 PancreatitisShock liver.NFGNB sepsis 33 RANJIT 0.848 0.813 0.901 0.742 0.667
0 1 1 1 0 0 1 7 34 DIVYA 10 10 HT+NT+LS0.749 0.609 0.886 0.873 0.792
1 1 1 1 0 0 1 11 Right lower lobe pneumoniaH1N1 su erinfection 35 SRIRAMALUD1-10, D2-4N HT+RF+LS0.787 0.81 0.771 0.691 0.659
1 1 1 1 0 2 0 9 Cardiogenicseptic shock, myocarditis, 36 AMBIKA 0.845 0.757 0.732 0.683
1 1 1 1 0 9 1 9 37 SELVI 4 18 NT+SEPSIS+FASCIOTOMY0.797 0.76 0.76 0.637 0.666
0 1 1 0 0 0 1 7 38 TAMILSELVAN10 8 HT+NT+LS0.883 0.782 0.658 0.483
0 1 1 1 0 0 1 7 39 SRIDHAR 8 12 HT+NT+LS0.771 0.665 0.582 0.855 0.835
0 0 1 0 0 0 1 3 RTA 40 PUSHPALATHA6 4 HT+LS 0.804 0.757 0.76 0.744 0.71
1 1 1 1 1 5 1 9 Sheehans syndrome 41 KUMAR 0.523 0.848 0.847 0.738 0.739
0 1 1 1 0 5 1 9 Uraemic pleural effusion 42 SOLLARAJAN10 26 0.963 0.797 0.662 0.644 0.905 0.888
0 0 1 1 0 0 1 7 43 PALANI 0.403 0.331 0.352 0.331 0.421
0 1 1 1 0 4 1 9 Cardiogenicseptic shock, myocarditis, 44 GURUVIAHD1-6, D2-6 1 HT+NT+LS0.379 0.431 0.244 0.351 0.269
1 1 1 1 0 5 1 9 Sheehans syndromeacute angle closure glaucoma45 PONNUSAMY 0.271 0.272 0.289 0.299 0.283
0 1 0 0 0 2 1 5 VAP 46 DEVARAJALU 0.349 0.324 0.315 0.305
0 0 1 1 1 0 1 6 47 SARATH KUMAR 0.28 0.346 0.304 0.236 0.28
1 1 1 1 0 2 1 9 ESBL E coli UTI 48 SANJU REDDY 0.311 0.264 0.24 0.275 0.289
0 1 1 1 0 0 3 7 Cardiogenic shock with myocarditis 49 MAHESHWARI 0.37
0 0 0 0 0 0 1 5 50 VALARMATHI 0.329 0.385 0.282 0.299
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116 18 M RLL 5/5/2015 0 1 1 1 0 0 1 10 2 N 1 1 1 1 1
117 28 M RUL 5/5/2015 4 1 1 1 1 1 0 26 2 N 1 1 1 1 0
118 31 M LLL 5/10/2015 0 0 0 0 0 0 0 0 NA N 0 0 0 0 0
119 32 F LLL 5/14/2015 4 0 0 0 0 0 0 14 6 N 1 1 1 1 1
120 15 M RUL 5/13/2015 23 0 0 0 0 0 0 23 4 N 1 1 1 1 1
121 54 M RUL 5/16/2015 NA 0 0 0 0 0 0 12 4 N 0 0 0 0 0
122 29 M LLL 5/20/2015 0 1 1 1 1 1 1 10 8 N 1 1 1 0 0
123 38 M RUL 5/21/2015 4 1 1 1 1 1 0 14 1 N 1 1 1 0 0
124 30 F RUL 5/21/2015 7 0 0 0 0 0 0 13 1 N 1 1 1 1 1
125 47 M LLL 5/29/2015 0 0 0 0 0 0 0 16 3 N 1 1 1 1 1
126 40 M RLL 5/30/2015 5 1 1 1 1 1 1 15 2 N 1 1 1 1 1
127 25 M RLL 6/6/2015 10 0 0 0 0 0 0 30 1 N 1 1 1 1 1
128 30 M RUL 6/4/2015 24 0 0 0 0 0 0 24 2 N 0 0 0 0 0
129 35 M RLL 6/8/2015 5 0 0 0 0 0 0 15 2 N 1 1 1 0 0
130 56 M RLL 6/10/2015 0 0 0 0 0 0 0 10 2 N 1 1 1 0 0
131 39 M LLL 6/24/2015 6 0 0 0 0 0 0 16 6 N 0 0 0 0 0
132 36 F Unknown 7/1/2015 NA 1 1 1 1 1 1 10 2 N 1 1 1 1 1
133 31 M LUL 7/2/2015 4 1 0 0 0 1 0 14 2 N 1 1 1 0 1
134 40 M LLL 7/7/2015 10 0 0 0 0 0 0 20 3 N 1 1 1 1 1
135 60 M RUL 7/14/2015 10 1 1 1 0 1 0 23 2 N 1 1 1 0 0
136 54 F RLL 7/18/2015 0 1 1 1 1 1 1 20 1 N 0 0 0 0 0
137 55 F LLL 7/22/2015 0 0 0 0 0 0 0 0 NA Y 0 0 0 0 0
138 48 F RLL 7/21/2015 18 1 1 1 1 1 1 28 6 N 1 1 1 1 1
139 46 M RLL 7/24/2015 3 1 1 1 1 1 1 23 2 N 1 1 0 1 0
140 32 M RLL 7/25/2015 6 0 0 0 0 0 0 16 3 N 1 1 1 1 0
141 45 M LLL 7/31/2015 40 0 0 0 0 0 0 40 4 N 1 1 1 0 0
142 63 F LLL 8/2/2015 16 0 0 0 0 0 0 16 2 Y 1 1 1 1 1
143 35 F LUL 8/6/2015 0 0 0 0 0 0 0 2 30 N 0 0 0 0 0
144 28 F LLL 8/6/2015 0 0 0 0 0 0 0 10 2 N 0 0 0 0 0
145 18 M RLL 8/5/2015 NA 0 0 0 0 0 0 10 NA N 1 1 1 1 1
146 45 F RLL 8/8/2015 4 1 1 1 1 1 1 14 1 N 0 0 0 0 0
147 45 F LUL 8/9/2015 0 0 0 0 0 0 0 10 2 Y Cobra(live snakes)1 1 1 1 1
148 40 M LLL 8/7/2015 20 0 0 0 0 0 0 30 2 N 1 1 1 0 0
149 52 F RLL 8/8/2015 0 0 0 0 0 0 0 10 3 Y Russels Viper 0 0 0 0 0
150 60 M LLL 8/12/2015 23 0 0 0 0 0 0 23 3 N 1 1 1 1 0
151 40 F LUL 8/14/2015 12 0 0 0 0 0 0 22 3 N 1 1 1 1 0
152 36 F LUL 8/15/2015 3 0 0 0 0 0 0 13 4 N 1 1 1 0 0
153 20 M RLL 8/20/2015 6 0 0 0 0 0 0 22 2 Y Saw scaled Viper0 0 0 0 0
154 36 M LLL 8/23/2015 1 1 1 1 1 1 0 9 4 N 1 1 1 1 1
155 54 M LUL 8/27/2015 10 0 0 0 0 0 0 10 6 N 0 0 0 0 0
156 65 F RLL 9/2/2015 20 0 0 0 0 0 0 30 4 N 1 1 0 0 0
157 47 M LLL 9/19/2015 NA 0 0 0 0 0 0 10 NA N 1 1 1 1 1
158 20 M RLL 9/17/2015 8 0 0 0 0 0 0 28 1 N 1 1 1 1 1
159 65 M LLL 10/17/2015 0 0 0 0 0 0 0 10 4 N 1 1 1 1 0
160 50 M RLL 10/4/2015 10 0 0 0 0 0 0 30 1 N 0 0 0 0 0
161 22 F LLL 10/6/2015 10 0 0 0 0 0 0 20 3 N 1 1 1 0 0
162 30 M LLL 10/19/2015 10 0 0 0 0 0 0 10 1 N 0 0 0 0 0
163 55 M RLL 10/14/2015 18 0 0 0 0 0 0 0 2 0 0 0 0 0 0
164 46 M RLL 10/21/2015 10 0 0 0 0 0 0 10 2 N 0 0 0 0 0
165 35 M RLL 11/8/2015 25 0 0 0 0 0 0 25 6 N 1 1 1 0 1
166 37 F RLL 11/25/2015 10 0 0 0 0 0 0 10 6 N 1 1 1 1 1
167 17 M RUL 11/29/2015 8 0 0 0 0 0 0 18 3 N 0 0 0 0 0
168 46 M RUL 12/30/2015 8 0 0 0 0 0 0 23 3 N 1 1 0 0 0
169 16 M RLL 1/5/2016 8 0 0 0 0 0 0 10 2 N 1 1 1 0 0
170 54 F RLL 1/11/2016 12 0 0 0 0 0 0 24 6 N 1 1 1 1 1
171 20 M LLL 1/23/2016 10 0 0 0 0 0 0 18 3 N 1 1 1 1 1
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0 3 3 3 0 1 > 20 m 17.8 39.3 11.5 0 0 0 1 1 4 1 1 1 0 1 8
0 4 5 2 0 1 > 20 m 87 29.3 0 0 4107 0 1 1 3 0 1 0 1 1 0
0 0 0 0 0 1 > 20 m 11.4 24 0 0 777 11600 1 1 5 1 1 1 1 1 13
1 4 5 3 3 0 < 10 m 10.7 31.8 0 0 94 0 0 0 0 0 0 0 0 0 0
0 4 5 4 0 1 < 20 m Clot clot clot clot 3073 0 1 1 1 1 1 1 0 0 0
0 0 0 0 0 1 < 20 m 18.2 26.5 13.1 0 3132 1161 0 0 1 0 0 0 0 0 0
0 3 4 0 0 1 < 15 m 35.9 45.3 12.2 37.3 0 0 0 0 3 1 0 0 0 0 0
0 2 2 0 0 1 > 20 m 16.1 62.5 11.4 55.4 0 0 1 1 1 0 1 0 0 0 0
0 4 5 2 0 0 > 20 m 13.4 26.2 11.5 0 696 0 0 0 0 0 0 0 0 0 0
0 3 4 4 0 1 > 20 m >2 min >3 min 14.1 70.6 375 0 1 1 2 1 1 0 0 1 0
0 3 4 2 0 1 > 20 m 24.5 33.3 12.3 0 610 0 1 1 4 1 1 1 0 1 0
0 4 5 1 0 1 > 20 m 39.2 36.1 12.9 0 0 0 1 1 1 1 1 1 0 0 0
0 0 0 0 0 1 > 20 m 15.2 52.7 11.4 47.5 50 412.9 1 1 3 1 1 0 0 1 0
0 5 5 0 0 1 > 20 m 25.2 34.5 0 0 19060 4340 1 1 4 1 1 0 1 1 7
0 2 2 0 0 0 < 20 m 10.2 36.7 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 1 > 20 m 35.2 61 11.6 37.5 96 827.4 1 1 2 1 1 1 0 0 0
0 4 5 4 4 0 < 20 m 9.9 31 0 0 0 0 0 0 0 0 0 0 0 0 0
1 3 3 0 3 0 < 20 m 10.9 28.7 0 0 0 0 0 0 0 0 0 0 0 0 0
0 3 3 2 0 1 > 20 m 59.2 30.6 13 0 0 0 0 0 1 0 0 0 0 0 0
0 4 5 0 0 1 < 20 m 11.9 36.8 11.2 0 252 0 1 0 1 0 0 0 0 0 0
0 0 0 0 0 1 > 20 m >2 min >3 min 12.5 25.5 143 0 0 0 1 0 1 0 0 0 0
0 0 0 0 0 0 < 10 m 9.9 31.1 0 0 260 0 0 0 0 0 0 0 0 0 0
0 3 4 1 0 1 > 20 m 13.7 34.3 11.1 0 1365 9460 1 1 6 1 1 1 1 1 4
0 2 0 2 0 1 > 20 m >2min >3min 0 0 321 756 1 1 1 1 1 0 1 0 0
0 1 1 1 0 0 < 20 m 9.9 35.3 0 0 0 0 0 0 0 0 0 0 0 0 0
0 2 2 0 0 1 < 20 m 10.9 36.5 0 0 914 0 1 1 1 1 1 0 0 0 0
1 3 4 1 1 0 < 20 m 11.3 25.1 0 0 5659 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 < 20 m 10.9 33 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 1 < 20 m 17.2 25.7 11.8 0 72 499 0 0 1 0 1 0 0 0 0
0 4 5 3 0 0 < 20 m 14.6 34.3 10.9 0 699 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 1 > 20 m 57.5 37.8 11.7 0 0 0 1 1 1 0 1 0 0 0 0
0 2 2 1 0 0 < 20 m 10.5 29.8 0 0 240 0 0 0 0 0 0 0 0 0 0
0 3 4 0 0 1  > 20 m 21.4 53.2 12.4 40.2 1 2340 1 1 5 1 1 0 0 1 6
0 0 0 0 0 1 > 20 m 22.1 44.4 12 28 69 0 0 0 1 0 1 0 0 1 0
0 4 5 1 0 1 < 20 m 11 32 0 0 656 1511 0 0 1 0 0 0 0 1 0
0 4 4 2 0 1 < 20 m 12 38 0 0 94 2225 0 0 1 1 1 0 0 1 0
0 2 3 0 0 1 > 20 m >2 min 26.9 12.7 0 396 0 0 0 3 0 1 0 0 1 0
0 0 0 0 0 1 > 20 m >2 min 76.5 12.4 44.3 0 0 0 0 1 0 1 1 0 0 0
1 4 5 4 3 1 > 20 m > 2 min > 3 mins 12.6 25.4 565 0 1 1 1 1 1 1 0 0 0
0 0 0 0 0 1 < 20 m 12.6 34.1 11.2 0 130 0 1 1 1 1 1 0 0 1 0
0 3 0 0 0 1 > 15 m 17.4 34.3 12 0 657 7340 1 1 3 1 1 1 0 1 12
0 1 2 2 0 0 < 20 m 10.9 34.8 0 0 246 0 0 0 0 0 0 0 0 0 0
0 3 3 1 0 1 > 20 m > 2 min > 3 mins 13.8 50.2 287 1385 1 1 2 1 1 1 0 0 0
0 1 1 1 0 0 < 20 m 11.8 23 1.1 0 449 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 1 > 20 m > 2min 125 12.1 31 342 0 1 1 3 1 1 0 0 0 0
0 3 3 1 0 1 > 20 m 24.5 34.4 12.4 0 1550 0 1 1 1 0 1 0 0 0 0
0 0 0 0 0 0 < 15 m 9.9 39.7 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 < 20 m 11.1 30 0 0 2447 0 0 0 0 0 0 0 1 0 0
0 0 0 0 0 1 < 20 m 11 38.5 0 0 0 0 0 0 1 0 0 0 0 0 0
0 4 5 0 0 1 > 20 m 19.5 58.5 11.9 48.9 26491 0 1 0 4 1 1 0 0 1 0
0 2 2 2 0 1 > 20 m 28.3 68 12.3 51.8 142 0 0 0 3 1 1 0 1 0 0
0 0 0 0 0 1 > 20 m 31.9 34 11.3 0 0 0 0 0 1 0 1 0 0 0 0
0 3 0 0 0 1 > 20 m >2 min 69 14 29.1 342 0 1 1 3 1 1 1 0 1 4
0 3 4 0 0 1 > 20 m 22.8 35 11.6 0 563 0 1 0 2 1 0 0 0 0 0
0 5 6 2 0 1 < 20 m 14 32 11.4 0 1277 845 0 0 4 1 0 0 1 1 6
0 4 5 2 0 1 > 20 m Lysed Lysed 0 0 1448 0 1 1 2 0 1 1 0 0 0
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1 1 1 1 0 14 1 9 Cardiogenic shock with myocarditis 51 BF ASV PREMKUMAR 0.64 0.539 0.469 0.442 0.502
0 1 1 1 0 2 1 9 52 RAJA 0.528 0.51 0.451
1 1 1 1 0 0 1 11 Plasmapheresis- improvedATN in renal biopsy with proliferative glomerulopathy53 RAMADAS SURESH 0.928 0.907 0.612 0.492 0.498
0 0 0 0 0 2 1 5 54 ANITA 0.467 0.406 0.388 0.546 0.548
0 1 1 1 1 5 1 7 GNB Pneumonia 55 RAMKI 0.47 0.449 0.542 0.518 0.47
0 1 1 1 0 0 1 3 Rhabdomyolysis 56 GOVINDRAJ 0.449 0.542 0.534 0.52 0.514
0 0 1 1 0 2 1 7 ASV ANAPHYLACTIC SHOCK 57 RAMESH 0.424 0.335 0.388 0.398 0.416
0 0 1 1 0 0 1 7 58 NARAYAMOORTHY 0.421
0 0 1 1 0 0 1 6 59 ANNAPOORNA 0.294 0.311 0.361 0.357 0.294
0 1 1 1 1 0 1 9 60 PALANI 0.575 0.366 0.357 0.293 0.308
0 1 1 1 0 3 1 9 61 ARUMUGAM 0.339 0.221 0.266 0.253 0.352
0 0 1 1 1 3 1 7 Crush injury feet 62 MURUGAN 0.315 0.294 0.318 0.293 0.294
0 0 1 1 0 2 1 11 63 SATHAKUMAR 0.317 0.33 0.369 0.504 0.301
1 1 1 1 0 0 1 9 64 THULASIRAM 0.44 0.532 0.395 0.313 0.291
0 0 0 0 0 0 1 5 65 RAJENDRAN 0.215
0 0 1 1 0 2 1 3 Delayed ophitoxemia- left cerebellar hemorrhage with mass effect66 SIVA REDDY 0.378 0.467 0.25 0.312
0 0 0 0 0 2 1 5 67 NAVENNETHAN 0.288 0.228 0.238
0 0 0 0 0 2 1 5 68 CHIRANJEEVI 0.33 0.335 0.296
0 0 1 1 0 0 1 7 69 SUBHA REDDY 0.225 0.318 0.456 0.239
0 0 1 1 0 0 1 7 70 DHANDAPANI 0.229 0.324 0.428 0.225 0.32
0 0 1 1 0 0 1 3 ASV ANAPHYLAXIS, TYPE 2 MYOCARDIAL INFARCTION71 SUSHEELA SELVAKUMAR 0.409 0.389 0.374
0 0 1 1 0 0 1 2 72 MEERA 0.313 0.381
1 1 1 1 0 5 1 9 ATN in renal biopsy 73 BANU 0.403 0.529 0.155 0.214 0.182
0 0 1 1 0 0 1 7 74 VENKATACHALAN 0.413 0.335 0.347 0.411
0 0 1 1 0 0 1 6 75 NATARAJ 0.336
0 1 0 0 0 3 1 8 NFGNB Pneumonia 76 MAHABOOB BASHA 0.446 0.358 0.309
0 1 1 1 1 6 1 6 Transient myocarditis, post cardiac arrest, aspiration pneumonia 77 VIJAYA 0.306 0.32 0.318 0.305 0.303
0 0 0 0 0 0 1 2 78 SARASWATHI 0.355
0 0 1 1 0 0 1 3 79 SATHYA 0.358
0 0 0 0 0 4 1 5 80 RANJIT KUMAR 0.347 0.386
0 0 1 1 0 0 1 3 81 VALLIAMMAL 0.641 0.465 0.404
0 0 1 1 0 0 1 6 82 MEENA 0.421 0.575 0.427
1 1 1 1 0 9 1 9 Resolving ATN.Pseudomonas sepsis 83 PERUMAL 0.375 0.342 0.404 0.361 0.313
0 0 1 1 0 0 1 11 84 SARASWATHI 0.361 0.373
0 1 1 1 0 0 1 9 85 BALARAMAN 0.347 0.341
1 1 1 1 0 0 1 9 86 JAYANTHI 0.375 0.354
0 1 1 1 0 0 1 9 87 BHARATHI 0.453 0.335
0 0 1 1 0 0 1 3 88 DHANASEKAR 0.369
0 0 1 1 0 8 1 7 Right hemiplegia, watershed infarct, GNB Sepsis,VAP89 DEVANDRAN 0.709 0.545
1 0 1 1 1 0 1 11 90 RANGAREDDY 0.306 0.287 0.305
1 1 1 1 0 6 1 9 myocarditisGNB sepsis /pneumonia 91 PANCHALI 0.288 0.306 0.311
0 0 1 1 1 3 1 6 92 RAJA 0.401
0 0 1 1 0 0 1 7 93 KUMAR 0.35 0.332
0 0 1 1 0 0 1 6 94 MUNUSAMY 0.338
0 0 1 1 0 0 1 3 95 SAKRAVARTHI 0.351 0.315 0.351
0 1 1 1 0 0 1 7 96 MAMTHA 0.339 0.312 0.31
0 0 1 1 0 0 1 2 97 UMA MAGESWARI 0.303 0.343 0.338
0 1 1 1 0 0 1 2 98 RAJENDRAN 0.298
0 0 1 1 0 0 1 3 99 CHINNAPA 0.317
0 1 1 1 0 0 1 9 100 PARASIVAM 0.315 0.31 0.649
0 0 1 1 0 2 1 7 101 AMUL 0.345 0.293
0 0 1 1 0 0 1 3 102 GOPI 0.958
1 1 1 1 0 6 1 9 103 SELVAN 0.778 0.313 0.339 0.451
0 1 1 0 0 0 1 7 104 MOORTHY 0.277 0.314
1 1 1 1 0 6 1 9 105 GOVARTHANA 0.246
0 1 1 1 0 4 1 7
